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ii. Abstract  
 Photodynamic therapy (PDT) is a relatively recent medical technique to treat various 
types of surface tumours. It unites two non-toxic components, a photosensitizing agent and 
laser light of a specific wavelength to induce tissue damage through the formation of 
reactive oxygen species. Exogenous administration of 5-aminolaevulinic acid (5-ALA) leads to 
an accumulation of the photosensitive protoporphyrin IX (PpIX) within cells. This molecule is 
formed throughout the haem biosynthesis pathway and by increasing its intracellular 
amount it becomes possible to induce targeted necrosis of tumour tissue. In the last step of 
the haem biosynthesis pathway the enzyme ferrochelatase converts its substrate PpIX into 
haem by the insertion of ferrous iron. The enzyme can be effectively inhibited by bidentate 
iron chelators deriving from 3-hydroxypyridin-4-one (HPO). The enhanced photodynamic 
effect of the combined treatment with both 5-ALA and a HPO derivative has been proven in 
recent studies.  
The synergistically acting drugs can be combined in a dendrimer to improve both the 
pharmacokinetics and the compliance of treatment. Dendrimers possess an increased ability 
to target malignant tissue and are therefore favoured molecules for the use in cancer 
treatment.  
 At the present, chemists at the department of Medicinal Chemistry at King’s College 
London are involved in the synthesis of HPO-derivative containing dendrons for the 
application in PDT. The aim of this 4 months lasting Diploma thesis project was to synthesize 
a first generation dendron containing three ester bonded terminal HPO-derivative moieties. 
A carbon chain length of six or eight between the pyridinone ring and the ester grouping of 
the branching unit had been previously proven to be most appropriate in terms of 
lipophilicity and cellular uptake.  
The two benzyl-protected iron chelators were prepared from ethyl maltol in two steps 
applying efficient and high-yielding procedures. The first attempts to establish a triol building 
block, consisting of a protected β-alanine linking unit and a tripodal branching unit, could not 
be successfully achieved. Using the tripodal branching unit without the protection of its 
hydroxyl groups, difficulties occurred when it was tried to couple it to β-alanine via amide 
bond formation. Having investigated different types of protective groups for both the triol 
branching unit and β-alanine, a four-step synthetic route finally led to the triol building block 
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in a good yield. The introduction of acetate esters as hydroxyl protective groups allowed the 
amide coupling and afforded the desired compound upon saponification of the acetates. The 
last step consisted of coupling the HPO-derivatives to the erected building block through 
ester bond formation and could only be partially achieved due to the limited time that was 
available for the project. 
In following synthetic attempts it will be tried to modify the conditions of this last reaction 
and to synthesize further similar dendrons that can be assembled to dendrimers together 
with 5-ALA containing compounds for tests in biological studies. 
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iii. Zusammenfassung 
Unter der photodynamischen Therapie (PDT) versteht man ein relativ neuartiges 
medizinisches Verfahren zur Behandlung von oberflächlich liegenden Tumoren. Das 
photodynamische Wirkprinzip vereint - mit einem photosensitiv wirksamen Agens und 
Laserlicht spezifischer Wellenlänge - zwei nicht-toxische Elemente in einer Art und Weise, 
dass durch die Bildung reaktiver Sauerstoffspezies (ROS) gezielt Gewebszerstörung induziert 
werden kann. Das exogene Zuführen von 5-Aminolävulinsäure (5-ALA) führt zum Anstieg des 
intrazellulären Protoporphyrin IX (PpIX) Spiegels. Dieses photosensitive Zwischenprodukt der 
Haem Biosynthese ermöglicht bei Bestrahlung mit Licht geeigneter Wellenlänge die 
zielgerichtete Zerstörung von Tumorgewebe. Im letzten Schritt des Biosynthesewegs 
verwandelt das Enzym Ferrochelatase sein Substrat PpIX durch den Einbau eines Fe++ Atoms 
in Häm. Zweizähnige Eisenchelatoren vom Typ der 3-Hydroxy-Pyridin-4-one (HPO) sind in der 
Lage,  dieses Schlüsselenzym effektiv zu inhibieren. In aktuellen Studien wurde gezeigt, dass 
die Kombinationstherapie mit 5-ALA und einem HPO Derivativ den photodynamischen Effekt 
um ein Vielfaches verstärken kann.  
Vereint man die beiden synergistisch wirksamen Pharmaka in einem einzigen Molekül, einem 
Dendrimer, dann verbessert dies sowohl die Pharmakokinetik der Wirkstoffe als auch die 
Compliance der Therapie. Dendrimere verfügen durch ihre außergewöhnliche Struktur die 
Gabe, spezifisch in Tumorzellen zu akkumulieren und eignen sich dadurch exzellent für die 
Anwendung in der Krebstherapie.   
Derzeit befasst sich eine Arbeitsgruppe des Departments für Medizinische Chemie am King’s 
College London mit der Synthese von Dendronen für die Anwendung in der PDT. Diese tragen 
HPO-Abkömmlinge als Endgruppen und werden im Zuge einer Zusammenarbeit mit der 
University of Essex gemeinsam mit 5-ALA enthaltenden Dendronen zu Dendrimeren 
zusammengesetzt.  
Ziel dieses Projekts im Rahmen der Diplomarbeit war die Synthese eines Dendrons erster 
Generation, welches drei terminale HPO-Derivative trägt, die über von den Pyridinringen 
ausgehenden Alkyl-Spacern durch Esterbindungen an eine dreifüßige Verzweigungseinheit 
gekoppelt sind. Ausgehend von Ethylmaltol wurden nach Schützung der Hydroxygruppe als 
Benzylether die Umwandlung in Pyridinderivate durch Umsetzung mit 6-Aminohexansäure 
und 8-Aminooktansäure in guten Ausbeuten erreicht.  
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Die ersten Versuche, einen geschützten β-Alanin-Linker über eine Amidbindung an eine 
ungeschützte Triol-Verzweigungseinheit zu knüpfen, waren nicht erfolgreich. Es wurden 
unterschiedliche Schutzgruppen sowohl für das Triol als auch für β-Alanin getestet und nach 
einigen Versuchen führte ein 4-stufiger Syntheseweg zum gewünschten Dendron-Block mit 
drei terminalen Hydroxygruppen. Als Schutzgruppen für die Triol Verzweigungseinheit 
wurden Acetatester eingeführt, welche nach erfolgreicher Amidkopplung an den β-Alanin-
Linker einfach durch Verseifung entfernt werden konnten. Der gewünschte Dendron Block 
wurde in guter Ausbeute erhalten. Der letzte Schritt, in dem diese Triol Einheit durch 
Esterbindungen an die HPO-Endgruppen geknüpft hätte werden sollen, war nur teilweise 
erfolgreich.  
Aufgrund des limitierten Zeitraums, der für den Eramus-Aufenthalt zur Verfügung gestanden 
ist, finden derzeit am King’s College London noch weitere Modifikationen an diesem letzten 
Syntheseschritt statt, um zu das gewünschten Dendron in ausreichender Menge und Reinheit 
zu erhalten. Weitere ähnliche Dendrons sollen schlussendlich mit 5-ALA beinhaltenden 
Abschnitten zu Dendrimeren zusammengefügt und auf ihre biologische Aktivität überprüft 
werden.  
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1 Photodynamic therapy  
The beneficial effects of phototherapy have been known by humans for more than three 
thousand years, but it was only in the past century that light in combination with 
photosensitizing agents has been used in oncology to treat various kinds of cancer. The term 
“Photodynamic Therapy” was first introduced in 1904 by the German scientist Hermann von 
Tappeiner, who discovered photodynamic action by chance when one of his students tested 
the toxic side effects of the dye acridine on paramecia under different light conditions. They 
found, that there exists a connection between the activation of the dye with light and the 
survival of the cells. From then onwards numerous scientists attempted to treat malignant 
tumors and diseases of the skin with the help of photosensitizing agents and light in the 
wavelength range absorbed by the photosensitizer[1].  
1.1 Mechanism of action 
 
Photodynamic therapy (PDT) is a cancer treatment that unites two non-toxic components, a 
photosensitizing agent and laser light of a specific wavelength, to induce tissue damage in a 
very precise way through the formation of reactive oxygen species (ROS). The photosensitive 
drug, usually a tetrapyrrolic macroycyle, is administered either intravenously or topical to the 
patient. After having equilibrated in the body, the photosensitizer accumulates in tumor cells 
with a remarkable selectivity towards normal cells. It is not completely understood why 
tumor cells and rapidly proliferating cells retain photosensitizers longer and in a higher 
amount compared to healthy tissue. This selectivity is probably due to the fact that the 
malignant tissue is surrounded by more blood vessels, less lymphatic drainages and 
furthermore shows a lower pH value of the interstitial fluid[2].   
Because the ratio of the accumulated photosensitive drug and therefore also the 
fluorescence is higher in malignant cells than in healthy tissue, a tumor can easily be 
detected by irradiation with red laser light[3]. There are two photophysical mechanisms in 
PDT that are responsible for the anti-cancer effects and both of them involve oxygen. 
The type II mechanism (Figure 1) is defined as an energy transfer process and it is believed to 
be the main reason for the oxygen-dependent phototoxicity of the drugs that are used in 
PDT. Once the tissue is radiated with red laser light, the photosensitizer absorbs a certain 
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amount of energy and is then promoted from its ground state into an extremely unstable 
singlet excited state. The activated drug molecule then experiences intersystem crossing to 
form a longer lived triplet excited state. From this state, the photosensitizer reacts with 
intercellular molecular oxygen and decays back to its ground state. At the same time singlet 
oxygen is created, which is the actual photodynamic agent. The singlet oxygen attacks lipids 
or proteins to form other reactive intermediates and radicals, which can further react with 
cellular biomolecules [1, 3-4].   
 
Figure 1: Photophysical mechanisms involved in PDT
[3]
 
 
The type I mechanism (Figure 1) is defined as a radical or redox reaction which involves a 
transfer of electrons or hydrogen atoms between the photosensitizer, excited to its triplet 
state, and neighboring molecules. This transfer results in radical intermediates which are 
able to initiate further chain reactions that lead to the phototoxic degradation of other 
biomolecules and cell death. In contrary to the type II pathway, the type I mechanism can 
also take place without the presence of oxygen [1, 3-4]. 
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1.2 The effect of photosensitizers on tumors 
 
The mechanisms of PDT-mediated cellular damage are complex and the knowledge about 
these processes is still limited. There exist three main mechanisms that induce tumor-tissue 
destruction. They are interdependent and combine a number of biochemical and molecular 
factors.  
Direct tumor-cell killing, one of these mechanisms, correlates to the homogenate distribution 
of the photosensitizer within the tumor as well as to the amount of oxygen that is present in 
the tissue. The decrease in the available amount of oxygen is a result of its constant 
consumption during the photochemical process and of the immediate response to the 
illumination with light.  
Vascular damage of the surrounding blood vessels is another reason for the efficacy of PDT. 
The tumor relies on their providence of nutrients and it has been reported that PDT leads to 
a microvascular collapse which results in both hypoxia and anoxia.  
According to Mladen Korbelik and his colleagues, the immune host response is the reason for 
the complete elimination of cells that survive the effect of the photodynamic treatment in 
the first place. The production of inflammatory cytokines is upregulated as a response to 
PDT, furthermore it has been reported that lymphocytes, leukocytes and macrophages 
infiltrate the tissue in a higher amount after such treatment[5]. 
1.3 Light irradiation and sources of light used in PDT 
 
The choice of a suitable device as the source of light depends on the light absorption 
maximum of the photosensitizing drug. One of the first drugs used in clinical PDT was 
haematoporphyrin derivative (HpD), which is activated when illuminated with light in the 
near-UV, at a wavelength of around 400 nm. Unfortunately, the living tissue which is 
penetrated by laser-light, effectively absorbs at this exact wavelength and therefore reduces 
the effectiveness of the treatment. An ideal photosynthesizing drug is thus activated at 
wavelengths > 600 nm in order to ensure a better absorption of tissue-penetrating red-light. 
Light at these wavelengths also holds the advantage of being able to reach deeper-lying 
tumors[3]. Due to this circumstance light sources with an output of light at the red region of 
the spectrum and an improved tissue penetration have been introduced to PDT. 
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Initially, regular gas discharge lamps were used in PDT. They could only be applied to easily 
accessible parts of the skin and to superficial lesions. It was the revolutionary introduction of 
lasers attached to optical fibers that enabled an endoscopic light-delivery to reach nearly 
every organ of the human body. Today a wide range of lasers and lamps are available. The 
choice of the most suitable light source depends on many factors, such as the targeted 
organ, the type of photosensitizer, the ease of use and cost. The advantage of lasers as a 
source of light is that they are powerful and deliver monochromatic light at a distinct 
wavelength. The selection of the appropriate wavelength is crucial and has to correlate to 
the maximum absorption band of the photosensitizer. Due to these prerequisites, one laser 
can only be used in combination with a certain photosensitizing drug. Lamps, on the other 
hand, provide a wider spectrum of wavelengths and are often combined with a variety of 
filters to select specific wavelengths. They are easier and cheaper in use, but can only be 
applied to lesions on the skin[6].   
1.4 Photosensitizers in clinical PDT 
 
Although many chemical compounds can act as photosensitizers, only a few possess the 
correct properties to render them suitable for clinical trials. In clinical practice, there are 
three main groups – porphyrins, chlorophylls and dyes – from which photosensitizers derive. 
All clinically useful compounds are able to target malignant tissue and to be activated by light 
at a high enough wavelength that is appropriate for therapy.   
1.4.1 The porphyrin family[7] 
Photophrin® (Haematoporphyrin derivative (HpD), Formula 1) is the first systemically studied 
and most commonly used photosensitizer in PDT. Haematoporphyrin is obtained from acid-
hydrolyzed haem or haemoglobin and is then treated with further chemicals to result in a 
mixture of monomers, dimers and oligomers of the original compound. The complex 
combination of these derivatives is crucial for their efficacy. 
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Formula 1: Molecular structure of Photophrin®
[7]
 
 
Photophrin® is approved all over the world to treat different kinds of cancer, such as 
esophageal tumors, early-stage lung cancer and bladder cancer. This drug is relatively non-
toxic, reliable and most importantly, the treatment is pain-free. On the other hand, there are 
quite a few reasons, why HpD is not the ideal photosensitizer: the drug accumulates also in 
healthy tissue to a comparatively high level and is only slowly cleared from the system. This 
leads to a cutaneous photosensitivity to solar radiation, which sometimes lasts up to 4 weeks 
or longer.  
Another member of the porphyrin family is Verteporfin, a benzophyrin derivative that is used 
in a formula together with liposomes. It is activated at a higher wavelength than HpD and is 
therefore able to penetrate more deeply into the skin. Due to the fact that it accumulates in 
the targeted tissue very fast and is cleared rapidly, the risks of post-treatment 
photosensitization of the skin are comparatively low.  
A further subclass of the porphyrin-family is texaphyrin. This photosensitizer, which contains 
the paramagnetic metal gadolinium(III), selectively targets tumor-tissue and is detectable by 
magnetic resonance imaging (MRI). It has been used to support MRI scanning for a few years 
and as it is activated by light at a comparatively high wavelength, it is also a promising 
compound for clinical PDT[8].  
5-Aminolevulinic acid (5-ALA) is an endogenously occurring amino acid that represents the 
first step in the porphyrin synthesis pathway. Porphyrin metabolism leads to the production 
of haem in mammals. The photosensitive intermediate protoporphyrin IX is formed at a 
higher rate when 5-ALA is administered topically or systemically. The important role of 5-ALA 
and its derivates in PDT will be discussed in more detail in section 1.5..  
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1.4.2 The chlorine family[7] 
One of the members of the heterogeneous group of chlorine derivatives is Foscan® 
(Temoporfin). It possesses a high efficiency in light-converting and the duration of treatment 
declines to only a few minutes. The compound is used in chemotherapy for the treatment of 
various cutaneous lesions and tumors in the head and in the neck. However, there are clinical 
drawbacks: the systemic injection of the drug is associated with pain and due to its high 
activity, patients are photosensitive after treatment even to normal room-light.  
Purpurins, also belonging to this group, are chemically modified chlorophyll-derivatives and 
are currently used for the treatment of Kaposi sarcoma, basal cell and chest wall metastasis. 
Mono-L-aspartyl-chlorin e6 is another multifunctional and safe photosensitizer, but it lacks of 
tissue selectivity, especially at the dosage needed in PDT. The chlorine-based drug 
photochlor (HPPH), being effective and safe, shows high potential to become a clinical 
photosensitizer. 
1.4.3 The dye family[7] 
Out of the commonly used dyes, phthalocyanines and their relatives have the highest ability 
for clinical PDT. They are activated at wavelengths between 650 and 850 nm and because of 
their lipophilic character they are dependent on liposomal formulation. All of the clinically 
successful compounds are chemically well defined and similar to porphyrin. Their efficacy 
can be enhanced when they are connected to metals to form complexes. 
Photosens, a mixture of sulfonated aluminium phthalocyanines, has been used in clinical 
trials to treat various kinds of cutaneous and endobronchial lesions. 
1.5 5-Aminolevulinic acid in photodynamic therapy[9] 
 
In mammals, porphyrins are synthesized mostly in erythropoietic tissue and the liver. 
Throughout the haem biosynthetic pathway (Figure 2) they lead to the production of haem.  
 
Formula 2: 5-Aminolevulinic acid (5-ALA) 
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5-Aminolevulinic acid (5-ALA, Formula 2) plays an important role in this pathway, as it is the 
endogenous precursor for the formation of porphyrins. In the first step, glycine and succinyl 
coenzyme A (CoA) are condensed to form 5-ALA. This reaction is catalyzed by the enzyme 
ALA synthase, which is located in the inner membrane of the mitochondria.  The cytoplasmic 
enzyme ALA dehydratase then combines two molecules of 5-ALA to create porphobilinogen 
(PBG), the first intermediate of the pathway that includes a pyrrole ring. After that, four 
molecules of PBG are condensed to form a linear tetrapyrrole intermediate, which is 
subsequently brought to yield in the cyclic uroporphyrinogen III. The enzymes responsible for 
these steps are PGB desaminase (PGBD) and uroporphyrinogen III cosynthase (Figure 2). Four 
acetic acid carboxylic groups are removed from uroporphyrinogen III by the cytoplasmic 
uroporphyrinogen decarboxylase. The resulting molecule, coproporphyrinogen III, is further 
oxidized and decarboxylated by a mitochondrial enzyme to yield protoporphyrinogen IX. 
Protoporphyrinogen oxidase then removes six hydrogen atoms in the tetrapyrrole ring to 
form protoporphyrin IX (PpIX). Only these oxidized porphyrins are intensely colored. In the 
last step the enzyme ferrochelatase, which is embedded in the inner membrane of the 
mitochondria, inserts iron into the tetrapyrrole ring of PpIX to form haem [9-10]. The 5-ALA 
derived PpIX is able to act as a photosensitizer when it is activated by light at a suitable 
wavelength. 
 
Figure 2: The haem biosynthetic pathway
[11]
. 
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The regulation of haem synthesis 
Haem biosynthesis is regulated by the availability of the substrates as well as by the 
inhibition of the first enzyme in this pathway, the ALA synthase. These controlling 
mechanisms vary between the liver and the bone marrow. Depending on the type of tissue, 
there exists either an erythroid-specific or a housekeeping isoenzyme for the ALA synthase, 
which are encoded by different genes. These enzymes, which show a quite low activity, can 
be directly inhibited through negative feedback regulation by haem. The intracellular 
concentration of haem can also influence the rate of transcription, translation and the 
transportation of the enzyme to the mitochondria.  
Topical application of 5-ALA 
After about 4 to 14 hours of the topical application of ALA, the formed PpIX can be activated 
with light at a wavelength of approximately 400 nm and then be measured with 
spectrofluorometric methods. Depending on the concentration of ALA in the formula and on 
the duration of the exposure, PpIX is either only produced on the treated sites of the skin or 
in larger amounts it can also lead to a generalized photosensitivity. As an adverse reaction, 
most of the patients suffer from an itching and burning feeling at the light-exposed areas of 
the skin which can last up to a few hours after the treatment. This side effect can be 
diminished when lignocaine in various concentrations is used either formulated in a cream or 
as an intracutaneous anaesthetic.  
Systemic administration of 5-ALA 
It is not completely clear whether the exogenous administration of 5-ALA is toxic. It has been 
reported, that the systemically applied drug can cause a temporary feeling of nausea and 
sometimes leads to transitory abnormal liver functions. Neurotoxic effects have not been 
observed below a dose of 60 mg/kg for oral and 30 mg/kg for intravenous administration. 
Despite the fact, that the 5-ALA plasma levels of cancer patients in PDT treatment are much 
higher than the plasma levels of porphyric patients, they do not suffer from the typical 
symptoms that are related to porphyria (severe neurologic deficits, vomiting, seizures). The 
reason for this phenomen is not clear and careful use of the drug is recommend when 
people with porphyria and liver or kidney problems are treated systemically with 5-ALA.  
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While the treatment of large lesions and tumors with systemically administered 5-ALA needs 
to be improved, ALA-based PDT appears to be an excellent choice for the treatment of 
smaller and more superficial malignant lesions of the aerodigestive tract, for instance 
dysplasia in the esophagus. 
1.6 Iron chelators in photodynamic therapy 
 
The enzyme ferrochelatase catalyses the last step of the haem biosynthesis (Figure 2 + Figure 
3). Haem is formed by the insertion of ferrous iron (Fe++) into the tetrapyrrole macrocycle of 
protoporphyrin IX (PpIX). The mechanism by which ferrochelatase catalyses this 
incorporation is only poorly understood. Ferrochelatase is located in the inner membrane of 
the mitochondrion and it is suggested that the porphyrins bind to an identified cleft, which 
also includes the metal-binding site of the enzyme[12]. 
PpIX acts as a photosensitizer in photodynamic therapy and can be produced at a higher rate 
if its precursor 5-ALA is exogenously administered. Inhibiting the enzyme ferrochelatase by 
limiting the intracellular iron supply is another way to increase the amount of PpIX. If the 
substrate is not readily available, the formation of haem is hindered and PpIX accumulates 
within the cells. Both of these approaches, the excessive administration of 5-ALA and the 
inhibition of ferrochelatase, enhance the formation of PpIX and therefore increase the 
effectiveness of photodynamic therapy[13].  
 
Figure 3: Insertion of iron via ferrochelatase
[14]
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1.6.1 The enzyme ferrochelatase 
Ferrochelatase is a key enzyme in the human haem biosynthesis pathway and its function 
closely correlates to the available amount of ferrous iron within the mitochondria. The 
protein consists of two identical domains and each of the subunits contains an iron-sulphur 
cluster. The enzyme’s association with the inner membrane of the mitochondria is achieved 
by the formation of a hydrophobic lip which also represents the entry to the active binding 
site of the enzyme[15]. It is proposed that the active site binds the substrate PpIX tightly and 
buries it completely to form an encapsulated hydrophobic pocket[16]. Hansson et al. 
investigated the properties of the ferrochelatase of Bacillus subtilis in order to gain better 
knowledge about the metal-binding residues for ferrous iron in the active site. They used 
site-directed-mutagenesis to prove that two conserved amino acids within the binding site, a 
histidine and a glutamic acid, strongly influence the enzyme’s affinity for iron. They found 
that the ferrous iron in the active site is coordinated by both of these amino acid residues 
and by three water molecules[17].  
Ferrochelatase and also the conversion of PpIX into haem can be inhibited by chelating the 
ferrous iron in the active binding site of the enzyme. Once the metal is chelated forming a 
stable ternary complex, the substrate’s access to the active cleft is denied and PpIX 
accumulates within the mitochondria. Considering the fact that the enzyme is partially 
embedded in the membrane and therefore surrounded by a lipophilic environment, only 
iron-chelating agents possessing a comparatively hydrophobic character are able to reach the 
described metal-binding site.  
1.6.2  Regulation of iron absorption and transport 
Iron is an essential metal for all eukaryotic cells and its uptake is regulated by various 
transport systems throughout the body. It can be obtained from diet by absorption in the 
gastrointestinal tract as well as from recycling old or damaged erythrocytes. In the blood 
serum, iron is bound to transferrin and internalized by cells via receptor mediated 
endocytosis. Within the cells, the metal is stored as a complex with the protein ferritin. The 
larger quantity of iron in the body is located in the hemoglobin molecules of erythrocytes 
and it is therefore necessary to make the intracellular iron available to the enzyme 
ferrochelatase in the mitochondria. A sufficient iron supply in the mitochondria is not only 
required for generating haem, but also for the biosynthesis of various iron-sulfur cluster-
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containing proteins. The exact mechanism of iron uptake into the organelles is not known, 
but it is suggested that it is driven energetically by a membrane potential along the inner 
mitochondrial membrane without the further need of ATP. The reduced (ferrous) form of iron 
is received by the ferrochelatase directly from the inner membrane and then inserted into 
PpIX[18].  
1.6.3 Inhibition of  mitochondrial  ferrochelatase 
Iron chelating compounds have mainly been used for the treatment of diseases that lead to 
iron overload within the human body. As an example, people who are suffering from β-
thalassemia and are treated with regular blood transfusions, accumulate iron in their system. 
As there are no mechanisms for iron excretion in humans, it is crucial for these people to be 
concomitantly treated with iron chelators. Desferrioxamine, a drug deriving from a bacterial 
siderophore, has been widely used in such cases. Because of its high molecular weight and 
hydrophilic behavior it has to be administered by injection and therefore lacks good 
compliance. To overcome these disadvantages, orally active bidentate iron chelators, 3-
hydroxypyridin-4-ones (HPOs, Formula 3) have been developed[19].  
Hydroxypyridinone (HPO) 1,2-diethyl  derivative (CP94)
 
Formula 3: Chemical structure of HPO and CP94 
 
Smith and coworkers conducted a study in which they added the orally active iron chelator 
1,2-diethyl-3-hydroxypyridin-4-one (CP94, Formula 3) to the drinking water of genetically 
modified mice. They observed the accumulation of porphyrins in the animals’ livers after one 
week of treatment. CP94, which belongs to the family of HPOs, has a low molecular weight 
and due to its lipophilicity it is able to penetrate through bio-membranes quite easily. The 
results of their experiments indicate that CP94 specifically chelates iron pools available to the 
ferrochelatase which leads to an increased intracellular amount of protoporphyrin. They 
assume that this chelator suppresses the mitochondrial iron deposit and also the transport 
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of the metal into the mitochondria. Besides the depletion of the ferrochelatase’s substrate, 
there is another explanation for the inhibition of the enzyme: the iron from the iron-sulphur 
cluster in the C-terminal area of the protein could be removed by the chelator and result in 
an inactive enzyme[20]. 
 In the same year, Si-Chung Chang and his group investigated the influence of CP94 on 
the amount of intracellular PpIX in different layers of the bladder after having intravesically 
administered 5-ALA to rats[21]. They found an enhanced formation of PpIX when CP94 was 
dosed to the animal and suggested various explanations for this phenomenon. In contrast to 
the hydrophilic desferrioxamine, members of the HPO family are lipophilic and therefore able 
to access intracellular iron pools more rapidly. Because iron is essential for the cell’s 
homeostasis, an interruption of the metal-metabolism can have antiproliferative and 
cytotoxic effects on malignant cell lines (for instance the metalloenzyme ribonucleotide 
reductase, which is a key enzyme in DNA synthesis, is also dependent on the availability of 
iron)[21].  
 In photodynamic therapy, the dose of orally tolerated 5-ALA is limited to 60 mg/kg. 
According to Curnow et al., the induced PpIX fluorescence within the mucosa of rat colons 
can be doubled if CP94 is administered together with 5-ALA. The subsequently produced 
area of necrosis was found to be three times larger than without the addition of chelator[22].  
 These observations were confirmed more recently by Pye et al. in 2008. They 
performed in vitro measurements of methyl-aminolevulinic acid induced-PpIX enhanced by 
CP94 on human cultured cells of dermatological origin and also in vivo studies including 
patients with nodular basal cell carcinoma. It was found that CP94 effectively increased the 
PpIX fluorescence in both circumstances. With this approach it becomes possible to reach 
also deeper layers of lesions. Thus, administering the same amount of 5-aminolevulinic acid, 
the additional CP94 is able to improve the photodynamic effect in thicker tumors. The 
antiproliferative effects of iron chelators, that have been previously shown, have not been 
proved in this study. This is probably due to the fact that CP94 is excreted rapidly by 
glucuronidation and all the effects on DNA synthesis are only of short duration[23].  
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All these investigations support the suggestion that the hydrophobic HPO-derivative CP94 is 
able to successfully inhibit ferrochelatase by chelating iron in the binding site of the 
molecule. As a consequence, the intracellular level of PpIX is increased. Together with the 
exogenous administration of the precursor 5-ALA, this leads to an enhanced effect in 
photodynamic therapy.  
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2 Dendrimers 
Traditionally, polymer chemists have focused on the synthesis of linear polymers. These 
molecules are widely used in everyday-life (for instance in plastics, fibres, adhesives, paints 
etc.). However, highly branched macromolecules, adopting a spherical shape, possess very 
different properties. Dendritic polymers are well-defined nanostructures with unique 
chemical properties and therefore used in a wide range of biomedical and industrial 
applications. Vöglte and his coworkers introduced dendrimer chemistry in 1978 by 
synthesizing “cascade molecules”. Tomalia et al. first published the synthesis of “starburst-
dendritic macromolecules” by using a divergent approach. ”Dendrimer”, which is the 
currently international accepted term, originally derives from the Greek words dendron 
(tree) and meros (part). Synonymous terms for this type of macromolecules are “arborols” 
and “cascade molecules”.  
A dendrimer (Figure 4) typically consists of three main structural components: a core, 
branches and end groups. Through successive sequences of stepwise reactions, more and 
more layers are added to the core molecule. Every additional layer leads to a higher 
generation dendrimer, which has double the number of end groups and about double the 
molecular weight [24],[25],[26]. 
A dendron (Figure 4) is just one section of a dendrimer and usually shaped like a wedge. It 
consists of multiple end groups and a single reactive site at the focal point. By attaching 
dendrons which contain different types of terminal groups to one centered core, it becomes 
possible to synthesize dendrimers with extended chemical properties [27].  
 
Figure 4: Left side: dendrimer, right side: dendron
[26]
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2.1 Synthesis of dendrimers 
 
There are two main strategies for dendrimer synthesis, divergent synthesis and convergent 
synthesis. Ideally, the size and the number of branches can be controlled by precise synthetic 
processes. When core, branches and end groups are featured with different chemical 
characteristics, it is also possible to regulate properties like thermal stability and water 
solubility. However, with either of the two main methods it is difficult to synthesize pure and 
inexpensive molecules, because the reaction procedure requires a high number of precise 
reactions which are problematical to bring to completion. Only a few compounds are 
commercially available.  
 In the divergent dendrimer growth method (Figure 5), the dendrimer is assembled 
outwards from a multifunctional core. A first generation dendrimer results from the reaction 
of the core molecule with suitable monomers. These monomers feature one reactive site and 
two or more protected or dormant groups. In subsequent steps, more monomers can be 
attached to the activated periphery of the first generation molecule. In this way, the 
dendrimer can be built layer by layer to form a highly symmetrical globule. Even though the 
divergent method can be used to synthesize large amounts of dendrimers, there are a few 
drawbacks. A major problem of this approach is, that as the molecule increases in size, the 
growth steps can become incomplete and those excess reagents may become necessary.  
Under such conditions considerable quantities of side-products accumulate, which causes 
difficulties in the isolation procedure of the desired compound [25-26].   
Figure 5: Schematic of divergent synthesis of dendrimers
[26]
 
 
In convergent dendrimer growth (Figure 6), more convenient and improved methods are 
applied that tend to avoid the disadvantages associated with the divergent synthesis. In this 
method dendrimers are built from the small end molecules on the outside of the sphere and 
are then linked with branching units to proceed inwards. The reaction takes place only at one 
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site of the growing dendrimer. Once the branching units are long enough they can be 
attached to a multifunctional core. With this method it is comparatively easy to purify the 
final product and it becomes possible to modify the peripheral functionalities of the 
dendrimer in a more precise way. Despite these advantages there is a limitation of dendrimer 
size compared to that produced by divergent method. Due to steric hindrance and problems 
with reactions between the dendrons and the core molecule it is not easy to synthesize 
higher generation dendrimers using this method [26, 28].  
 
Figure 6: Schematic of convergent synthesis of dendrimers
[26]
 
 
After the development of the convergent strategy other approaches to accelerate and 
simplify dendrimer synthesis have been investigated. In the early 1990’s Jean M. J. Fréchet 
and his group introduced the use of pre-assembled oligomeric species - hypercores and 
branched monomers. This new technique combines the advantages of the convergent and 
the divergent method in a way that the dendrimer can be synthesized in fewer steps and in 
higher yields. The double exponential and the mixed growth method (Figure 7) are further 
tactics that are similar to rapid growth methods of linear polymer chemistry.  
 
Figure 7: Double exponentional growth method in dendrimer synthesis
[24]
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In this approach only one branching moiety with two sites of protected functionalities is 
used. The separate deprotection of the surface as well as of the focal point of the branching 
unit leads to the formation of both a convergent-type and a divergent-type monomer. The 
reaction of these monomers results in an orthogonally protected trimer, which can be used 
for further growth steps[29]. 
2.2 Dendritic conjugates of 5-ALA and HPOs for the use in photodynamic 
therapy 
 
In the past decade the development of dendrimers for the use in bioscience has made an 
immense progress. The unique chemical properties of dendrimers render them suitable for 
applications in immunology and drug delivery, for instance the development of antivirals and 
vaccines. The synthesis of dendrimers that are biocompatible has led to new approaches 
especially in the field of cancer treatment, where these macromolecules seem to be the ideal 
drug delivery system to target tumor cells. Improved pharmacokinetics and increased 
photodynamic effects have been observed when low molecular weight therapeutic agents 
are derivatized on dendritic polymers[30].  
Dendritic conjugates of 5-ALA and iron chelators 
The precursor 5-ALA that is used in PDT does not possess the ideal properties for targeting 
malignant cells effectively. At pH 7,4 it is zwitterionic and relatively hydrophilic which means 
that the molecule is not readily taken up by cells and therefore shows a comparatively poor 
bioavailability. This limitation led to the investigation of 5-ALA-dendrimer conjugates. 
Recently, Battah et al. have been able to synthesize dendrimers bearing 18 5-ALA residues 
that showed improved pharmacokinetics and higher cellular uptake. The level of the 
photosensitizing PpIX within tumorigenic cells could be enhanced and a corresponding 
increase in light-induced cell destruction was measured[31].  
Not only the poor bioavailability of the prodrug 5-ALA, but also the conversion of the 
endogenously formed photosensitizer PpIX into haem has limiting effects on the efficiency of 
photodynamic therapy. As described previously, the combination of 5-ALA with iron-
chelating compounds can synergistically enhance PpIX levels caused by the inhibition of the 
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enzyme ferrochelatase. However, the main disadvantage of combining 5-ALA and HPO-
derivatives is the necessity of separately administering two drugs.  
In order to improve both the pharmacokinetics and also the compliance of this treatment, 
the properties of 5-ALA and HPO conjugates were investigated. In recent proof-of-principle 
studies several simple 5-ALA-HPO conjugates and small dendritic 5-ALA compounds 
containing a HPO were synthesized. These non-toxic conjugates, that enable a simultaneous 
delivery into the cell, were tested in-vitro in PAM 212 keratinocytes. They also achieved an 
enhanced accumulation of PpIX and light-induced cell death compared to 5-ALA alone 
(Unpublished data: SH Battah, AJ MacRobert, RC Hider). 
While in these test compounds only one HPO moiety was attached to 5-ALA esters or 
dendrons, increasing the number of coordinated HPOs could in principle lead to an even 
stronger PpIX fluorescence.  
Delivery of anticancer drugs by dendrimers and use in PDT 
Due to their complex and well-defined structural and sterical organization, dendrimers 
possess an increased ability to target malignant tissue and are therefore favored molecules 
for the use in cancer treatment. The effect that describes this phenomenon is called 
“enhanced permeation and retention (EPR)-effect”. Tumor cells are rapidly proliferating and 
dependent on the provision of nutrition from the surrounding blood vessels. Thus, the 
production of the vessels is stimulated. But, compared to the vasculature of normal tissue, 
their endothelial cells are defective and possess wider fenestrations and increased 
permeability. The lack of surrounding lymphatic drainage also contributes to the effect of 
accumulating macromolecules like dendrimers within the tumour.  
2.2.1 Bidentate iron(III)-selective chelators: 3-hydroxypyridin-4-ones (HPOs) 
When a ligand like 3-hydroxypyridin-4-one (HPO, Formula 3) possesses two donor atoms, it is 
classified as a bidentate iron chelator. Fe3+ is optimally coordinated once it is chelated to the 
metal centre by six donor atoms in an octahedral manner. Therefore, three HPOs form a 
complex together with one centred iron atom (Figure 8). The metal is coordinated by the 
chelators’ two vicinal oxygen atoms[32]. 
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Figure 8: Schematic representation of a chelate ring formation. Three bidentate ligands (HPO) form an 
octahedral complex with ferric iron 
 
One of the advantages of these Fe3+-selective ligands is their ability to chelate both ferrous 
and ferric iron under aerobic conditions. It has furthermore been shown that “high-affinity” 
Fe3+ ligands are capable of chelating ferrous iron and alleviate the metal’s autoxidation to 
ferric iron[33]. These circumstances explain why HPO-derivatives are able to inhibit the 
mitochondrial enzyme ferrochelatase, even though it utilizes ferrous iron for the insertion 
into its substrate PpIX. 
2.2.2 Synthesis of iron binding dendrimers  
Over the past five years, a wide range of iron-chelating dendrimers has been synthesized at 
King’s College London[34] [35] [36]. They have been prepared by both divergent and convergent 
routes and incorporate HPO-derivatives as iron chelating agents. The bidentate HPOs on the 
dendrimer surface range from three to 27 and are attached to the branching units via amide 
linkers.  
Zhou et al.[36] synthesized a range of iron(III) binding dendrimers for the potential use in a 
method of preventing iron overload. Dendritic chelators possess a high molecular weight and 
are not absorbed by the intestine. They are able to bind dietary iron and form nontoxic 
complexes that can be easily excreted in the feces. In a first synthetic route (Scheme 1) the 
hexadentate ligand 4 was synthesized by coupling three bidentate terminal HPO-ligands 2 to 
a tripodal triamine 1. The activated bidentate HPO end-groups 2 were prepared from maltol 
in eight steps. 
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Scheme 1: Synthesis of a hexadentate chelator
[35]
 
 
In a next synthetic route three of the previously described hexadentate ligands were 
combined in one dendritic chelator 10 (Formula 4), that possesses an extremely high affinity 
for iron(III). Employing the divergent synthetic route, the synthesis started off with the 
coupling of three ester-protected tripodal branching units 6 to a benzene tricarbonyl 
trichloride core 5. The resulting ester-protected compound 7 was treated with formic acid 
and diluted base to afford the deprotected molecule with the free amine groups 8.  
 
Scheme 2: Synthesis of a dendritic chelator using a multifunctional core, a tripodal branching unit and bidentate 
HPO-derivatives 
 
This step was followed by the amide formation with the activated pyridinone 2 (Scheme 1). 
The resulting first generation dendrimer 10 is shown in formula 4 after deprotection of the 
benzyl-protected dendrimer 9 (not displayed here). It contains three tripodal branching units 
attached to a multifunctional core and it is terminated by nine iron chelating HPO-
derivatives.  
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Formula 4: Hexadentate dendritic chelator based on a benzene tricarbonyl core polyamine dendrimer
[35]
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3 Aim of the project and synthetic schemes 
The aim of my four month project at King’s College London (KCL) was to gain more 
knowledge about organic chemistry and to synthesize one half of a first generation 
dendrimer (Formula 5) that might be used in photodynamic therapy. Dr. Tao Zhou is the main 
synthetic chemist in this project at KCL and has been working on dendrimeric chelators over 
the past five years[34-36]. Throughout the first weeks of my stay he was guiding me through 
the first synthetic attempts and I gradually became more acquainted with the working 
environment of this laboratory. During this time and also after Dr. Zhou’s departure to China I 
was advised by Professor Robert C. Hider, the lead scientist in the Medicinal Chemistry Group 
at KCL.  
The synthesis and the biological studies of these dendritic conjugates of the synergistically 
acting drugs 5-ALA and HPO are part of a collaborating project between the University of 
Essex and KCL. The left part of the first generation dendrimer in Formula 5, colored red, 
contains the 5-ALA moieties and is synthesized in Essex by the group of Dr. Sinan Battah[31, 37]. 
The other half of the dendrimer, colored blue (Formula 5), possesses HPO-derivatives as 
terminal groups. Both of these separate building blocks, or dendrons, are attached to a bi-
functional core through a linking unit, -alanine. The linkers are coupled to a tripodal 
branching unit via amide bonds, whereas the three HPO-derivatives and accordingly the 
three 5-ALA molecules are connected via ester bonds. The two dendrons will be assembled 
and biologically tested at the University of Essex.  
 
 
Formula 5: First generation dendrimer for photodynamic therapy containing both 5-ALA and HPO-derivative 
moieties 
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3.1 Synthesis of the HPO-derivatives 
 
The previously presented first generation dendrimer contains three terminating HPO-
derivatives with aliphatic alkyl spacers between the HPO rings and the ester groupings of the 
branching unit. Biological tests of single conjugates of 5-ALA and HPO with several different 
chain lengths of alkyl, polyethylenglycol and polyethyleneamine spacers revealed the most 
suitable spacers for the incorporation within the dendrimer. It was found that a carbon chain 
length of either six or eight is most appropriate in terms of lipophilicity and optimized 
cellular uptake. (Unpublished data: SH Battah, AJ MacRobert, RC Hider) 
In Scheme 3  it is shown how two HPO derivatives with a different length of carbon atoms in 
their aliphatic chain are prepared from benzyl-protected ethyl maltol. 
 
Scheme 3: Overall scheme for the synthesis of two different HPO derivatives, using ethyl maltol as a starting 
material 
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3.1.1 Synthesis of 3-benzyloxy-2-ethyl-pyran-4-one 
MW= 140,05
MW= 230,09  
Scheme 4: Benzylation of ethyl maltol 
 
The starting material for the preparation of the two different HPO-derivatives was 2-ethyl-3-
hydroxy-pyran-4-one (ethyl maltol). First it was necessary to protect the hydroxy group of 
ethyl maltol by benzylation (Scheme 4). Applying the Williamson ether synthesis method, the 
starting material was initially treated with sodium hydroxide in order to generate the 
nucleophilic alkoxide. The alkyl halide benzyl chloride was added dropwise and refluxed 
overnight. The nucleophilic alkoxide ion could therefore attack the electrophilic carbon atom 
of the benzyl chloride via an SN2 reaction and form the desired benzyl ether. The solvent was 
removed, the residue was dissolved in dichloromethane (DCM) and washed with 5% sodium 
hydroxide (NaOH), brine and finally with water. Diethyl ether was added to the concentrated 
residue and achieved precipitation of slightly yellow crystals when the solution was allowed 
to stand in the fridge overnight. The crystals, which were obtained in an acceptable yield, 
were washed with hexane/diethyl ether and used for the following step. 
The results from the 1H - nuclear magnetic resonance (1H-NMR) investigation clearly proved 
the presence of the protective benzyl group. The hydrogen atoms from the CH2-group of the 
benzyl group appeared as a singlet at a chemical shift of 5,10  parts per million (ppm), 
whereas the aromatic hydrogen atoms could be found as a multiplet at δ 7,24 – 7,33 ppm.  
The detailed synthetic procedure is described in section 5.1. 
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3.1.2 Synthesis of 3-benzyloxy-1-carboxypentyl-2-ethyl-4(1H)-pyridinone 
MW= 230, 09 MW= 131,18
MW= 343,18
 
Scheme 5: Synthesis of 3-benzyloxy-1-carboxypentyl-2-ethyl-4(1H)-pyridinone 
 
The conversion of the previously prepared benzyl-protected ethyl maltol into a pyridinone-
derivative is an amine insertion reaction. The mechanism that is accepted for this type of 
reaction involves the nucleophilic attack of the 4-pyrone by a primary amine. The 
nucleophilic amine targets the oxygen in the ring of the 4-pyranone, the ring is therefore 
opened and a molecule of water is eliminated. Subsequently, the ring closes again and 
affords the desired 4-pyridinone[38].  
As shown in (Scheme 5), 2-ethyl-3-benzyloxy-4-pyranone was refluxed overnight with the 
primary amine 6-aminohexanoic acid (aminocaproic acid) after the pH-value had been 
adjusted to 13 with NaOH. Once the reaction had been completed, the solution was acidified 
(pH 4) to achieve the precipitation of an oily mass. This oily precipitate was extracted from 
the aqueous phase with DCM and the organic phase was concentrated in vacuo. The residue 
was dissolved in the smallest possible amount of ethanol (EtOH) and then diethyl ether was 
added slowly until the appearance of a slight cloudiness. When the solution was stored in 
the fridge overnight, crystals formed in an acceptable yield and the desired HPO-derivative 
with a carboxypentyl-substitution on the ring nitrogen atom had been successfully achieved.  
The structure was determined by 1H-NMR and the two characteristic olefinic protons at 
position 5 and 6 of the pyridinone ring were observed at δ 6,69 and 7,42 ppm. The carboxylic 
proton was observed at δ 9,96 ppm. 
The detailed synthetic procedure is described in section 5.2. 
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3.1.3 Synthesis of  3-benzyloxy-1-carboxyheptyl-2-ethyl-4(1H)-pyridinone 
MW= 230, 09 MW= 159,13
MW= 371,21
 
Scheme 6: Synthesis of 3-benzyloxy-1-carboxyheptyl-2-ethyl-4(1H)-pyridinone 
 
The preparation of the analogue HPO derivative with a carboxyheptyl substitute at the ring 
nitrogen atom (Scheme 6) was initially carried out in exactly the same way as the previously 
described 3-benzyloxy-1-carboxypentyl-2-ethyl-4(1H)-pyridinone.  
 In this approach, it was more difficult than expected to obtain crystals in a good yield. 
The starting conditions for this reaction with 8-aminooctanoic acid were the same as the 
previously described reaction with aminocaproic acid. Once the reaction had finished and 
the pH-value of the aqueous solution lowered to 4, an oily mass precipitated from the water 
phase. After having extracted this oil with an organic solvent and concentrated it in vacuo, 
the residue was dissolved in a small amount of EtOH and diethyl ether was added to initiate 
precipitation of crystals. Several ratios of EtOH/diethyl ether and other solvents were 
investigated to induce the formation of crystals, but in most cases the phenomenon of “oiling 
out” occurred or the yield of the crystals was low (around 25%). 
 The literature was searched for ways of improving the yield of the compound and it 
was found that Katoh et al.[39] synthesized a similar HPO derivative in 2003 bearing a methyl 
group instead of the ethyl group in position 2. Following these instructions and modifying 
them slightly resulted in an acceptable high yield of crystals. The reaction was left to reflux 
for 48 hours instead of 24 hours and the aqueous solution was now acidified in two steps: 
firstly hydrochloric acid (HCl) was added until pH 8 was reached, followed by extraction with 
DCM to remove the remaining starting material (2-ethyl-3-benzyloxy-pyran-4-one). In the 
second step the solution was acidified with citric acid until pH 4 was reached and the desired 
compound precipitated out of the water phase as pale white flakes.  
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The structure was determined by 1H-NMR. The two characteristic olefinic protons at position 
5 and 6 of the pyridinone ring were observed at δ 6,57 and 7,34 ppm. The protons in the CH2 
groups of the carbon chain deriving from aminooctanoic acid could be easily assigned and 
distinguished from the signals of the protons in the HPO derivative with the attached 
aminocaproic acid.  
The detailed synthetic procedure is described in section 5.3 
3.2 Preparation of the tripodal branching unit  
4-amino-4-(3-hydroxypropyl)-1,7-heptanediol and attempt of 
coupling it with the Fmoc or Boc - protected linking unit β-alanine 
  
The scheme below (Scheme 7) shows the pathway for the synthesis of (9-methylfluoren-9-
yl)methyl-N-[3-[[4-hydroxy-1,1-bis(3-hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate 4, 
which consists of the fluorenylmethyloxycarbonyl (Fmoc) - protected linking unit β-alanine 3 
and the tripodal branching unit that is attached via an amide bond. The starting material 4-
(3-hydroxypropyl)-4-nitro-1,7-heptanediol (nitromethane-tris-propanol) 1 was successfully 
reduced in two different approaches to yield in crude 4-amino-4-(3-hydroxypropyl)-1,7-
heptanediol (bis-homotris[40]) 2. It was tried to attach the crude bis-homotris to Fmoc-β-
alanine through amide bond formation, but all of these attempts were unsuccessful. 
1 2
3
4
 
Scheme 7: Overall scheme for the synthesis of (9-methylfluoren-9-yl)methyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate (4) 
 
In another approach commercially purchased, pure bis-homotris was used for the coupling 
reaction with tert-butyloxycarbonyl (Boc) - protected β-alanine. Again, the coupling was not 
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successful even when different conditions and reagents were applied. This reaction is not 
shown in Scheme 7, but will be discussed in section 3.2.3. 
3.2.1 Synthesis of 4-amino-4-(3-hydroxypropyl)-1,7-heptanediol (Bis-homotris) 
Bis-homotris has been described in the literature by Newkome et al.[40] as “cascade building 
block” and is also commercially available. However, initially it was decided to synthesize this 
building block in order to circumvent increased costs due to the comparatively high price of 
the compound.   
Reduction of nitromethane-tris-propanol using Zn/HCl as reducing agents 
MW= 205,3MW=235,29
 
Scheme 8: Synthesis of 4-amino-4-(3-hydroxypropyl)-1,7-heptanediol using Zn/HCl as reducing agents 
 
In the first approach (Scheme 8), the nitro group of the commercially purchased 
nitromethane-tris-propanol was reduced to an amino group using Zinc (Zn) and HCl. The 
starting material was dissolved in EtOH and HCl was added dropwise while the zinc powder 
was added in small portions at room temperature. As there was no visible indication of 
effervescence, the temperature was increased and the mixture was refluxed until the thin 
layer chromatography (TLC) analysis revealed complete reaction. After the removal of the 
solid zinc powder, the solvent was evaporated and the residue was dissolved in ethyl acetate.  
 The organic phase was washed with a solution of sodium bicarbonate (NaHCO3), 
whereon bubbles of gas were welling up. Upon the addition of potassium bicarbonate 
(K2CO3) the aqueous solution turned white and creamy. This was done in order to 
deprotonize the product and to permit partition into the organic phase. The two phases were 
analyzed by TLC using a solution of ninhydrin in butanol and acetic acid in order to reveal the 
amino groups as purple spots. It was found that the entire product was present in the 
aqueous phase together with the inorganic salts that caused the white cream. Therefore, the 
salt was filtered off and the water was removed under reduced pressure using a strong 
pump. The residue, white crystals in an oily mass, was dissolved in methanol (MeOH) to 
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separate the salt from the compound. The inorganic salt was filtered off and the solvent was 
evaporated again. As there was still some salt present, the residue was dissolved in 
anhydrous isopropanol. Filtration and removal of the solvent afforded the crude product. 
Due to the highly hydrophilic character of bis-homotris, the work-up of the reaction was 
relatively problematic. Once the compound was present in the aqueous phase it was difficult 
to separate it from the inorganic salts.  
The detailed synthetic procedure is described in section 5.4.1. 
 
Reduction of Nitromethane-tris-propanol using Raney nickel as reducing agent 
MW= 205,3MW=235,29
Raney nickel
H2
 
Scheme 9: Synthesis of 4-amino-4-(3-hydroxypropyl)-1,7-heptanediol using Raney nickel as reducing agent 
 
In order to circumvent the difficulties that occurred in the previous method, the reduction of 
nitromethane-tris-propanol was attempted in the absence of water, using Raney nickel. In 
this approach (Scheme 9) nitromethane-tris-propanol was hydrogenated for 24 hours with 
specially prepared T-1 Raney nickel, which had been previously made following the 
instructions of Domingues et al.[41]. This reaction afforded the crude product in a good yield 
and seemed to be the superior choice of the two approaches for this reduction.  
The detailed synthetic procedure is described in section 0. 
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3.2.2 Attempt to synthesize (9-methylfluoren-9-yl)methyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate 
1) EEDQ 2) DCC, HOBt
 
Scheme 10: Attempt to synthesize (9-methylfluoren-9-yl)methyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate in two different approaches using EEDQ (1) and DCC/HOBt 
(2) as coupling agents 
 
As demonstrated in Scheme 10 pathway 1, the crude product of the previous reaction, Bis-
homotris, was reacted overnight at room temperature with Fmoc-β-alanine and the widely 
used coupling agent 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) in anhydrous 
dimethylformamide (DMF). The results of the TLC analysis indicated the formation of new 
products, but it was not completely clear which one should be isolated. The white precipitate 
was filtered off, DMF was removed under reduced pressure and the residue was dissolved in 
a small amount of ethyl acetate. This solution was passed through a silica gel column eluting 
with ethyl acetate/hexane (1:5) to achieve a separation of the different products. Mass 
spectrometry (MS) analysis of the collected fractions showed that none of the isolated 
tractions contained the desired compound.  
In pathway 2 the previously prepared Bis-homotris, Fmoc-β-alanine and the widely used 
peptide coupling agents N,N’-dicyclohexyl-carbodiimide (DCC) and 1-hydroxy-benzotriazole 
hydrate (HOBt) were reacted in anhydrous DMF and left to stir overnight at room 
temperature. Upon removal of the white precipitate, dicyclohexylurea (DCU), the solvent was 
removed and a yellow sticky residue was obtained. Analyzing a sample of this residue by MS 
demonstrated the absence of the desired.  
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The same reaction was also carried out with DCC alone and led thus to a similar result where 
no traces of the desired compound were detected on MS analysis. 
3.2.3 Attempt to synthesize tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate 
1) DCC, HOBt
2) DCC
 
Scheme 11: Attempt to synthesize tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-hydroxypropyl)butyl]amino]-3-oxo-
propyl]carbamate using DCC and HOBt (1) and DCC only (2) as coupling agent 
 
In the synthetic procedures from section 3.5.2 onwards, a Boc-group protected linking unit is 
used instead of the initially applied Fmoc protective group. The reasons for this will be 
explained in section 3.4 in more detail. While experimenting with this new protective group, 
another attempt was carried out to couple Bis-homotris directly to the Boc - protected β-
alanine linking unit. Moreover, this time commercially purchased, pure bis-homotris was 
used as a starting material for the reaction to investigate if the same problems occur with 
this material.  
Pathway 1 (Scheme 11) was carried out overnight at room temperature, using the coupling 
agents DCC and HOBt in anhydrous DMF. The instant formation of white precipitate (DCU) 
indicated that some kind of reaction had occurred, which was also visible on the TLC plate. 
Once the precipitate had been filtered off and the solvent had been removed, a sample of 
the residue was used for a MS-analysis to receive further information about the outcome of 
the reaction. The MS data showed peaks at the molecular weight of each of the three esters 
(Formula 6) and not of desired amide.  
 
Formula 6: Formation of the three esters instead of the amide 
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This is rather surprising, considering that amino groups are generally stronger nucleophiles 
than hydroxyl groups and should therefore attack the DCC - activated ester of Boc-β-alanine 
more rapidly[42].   
3.3 Synthesis of the N-hydroxysuccinimide ester of the linking unit Boc-
β-alanine and attempts to couple it with bis-homotris 
 
Earlier attempts to create an amide bond between the linking unit and the unprotected bis-
homotris using either DCC and HOBt or DCC only as coupling agents failed. This is probably 
due to the decreased nucleophilic character of the amino group in bis-homotris which is 
most possibly caused by the sterical influence of the hydroxyl groups forming multiple 
intramolecular hydrogen bonds. In a different approach (Scheme 12), the active N-
hydroxysuccinimide ester of Boc-β-alanine was synthesized and then it was tried to let it 
react specifically with the amino group of bis-homotris. The preparation of N-
hydroxysuccinimide esters is a common step in peptide synthesis in order to achieve amide 
bond formation in the presence of hydroxyl groups. As shown below it was only possible to 
prepare the ester, the desired coupling failed.  
After having observed all these difficulties associated with the use of the unprotected bis-
homotris, different approaches with protected derivatives were tried. 
 
Scheme 12: Overall scheme for the synthesis of tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate 
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3.3.1 Synthesis of the N-hydroxysuccinimide ester of Boc-β-alanine (((2,5-
dioxopyrrolidin-1-yl) 3-(tert-butoxycarbonylamino)propanoate) 
MW=189,21
MW=115,09
MW=286,11
DCC
 
Scheme 13: Synthesis of the N-hydroxysuccinimide ester of Boc-β-alanine 
 
As demonstrated in Scheme 13, the linking unit Boc-β-alanine and N-hydroxysuccinimide, 
which is an activating agent for carboxylic acids, were dissolved in dry ethyl acetate and 
reacted with the coupling agent DCC at room temperature. The mixture was stirred at 
overnight and stored in the fridge for a couple of hours to remove as much DCU as possible 
by precipitation. DCU was filtered off and the filter cake was washed with cold ethyl acetate. 
The combined filtrates were concentrated and white crystals formed at room temperature in 
a good yield. 
1H-NMR analysis supported the presence of the obtained N-OH-succinimide ester. The two 
CH2 groups adjacent to the carbonyl groups in the succinimide appear together with the -
CH2-COO-N< signal at 2,76-2,78 ppm. The infrared (IR) spectrum shows a sharp N-H 
stretching band at 3362 cm-1 deriving from the nitrogen next to the Boc-group. The C=O 
stretching bands from the cyclic imide ring appear at 1779 and at around 1700 cm-1. An 
amide I band appears at 1688 cm-1, whereas the amide II band can be found at 1523 cm-1. 
The detailed synthetic procedure is described in section 5.5. 
3.3.2 Attempt to synthesize tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate 
MW=286,11
MW=376,26MW=206,3
 
Scheme 14: Attempt to synthesize tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-hydroxypropyl)butyl]amino]-3-oxo-
propyl]carbamate 
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Scheme 14 shows the attempt of coupling the activated carboxylic acid and bis-homotris. Bis-
homotris was gently heated and stirred in order to dissolve completely in anhydrous DMF 
and then cooled to room temperature again. The N-hydroxysuccinimide ester of Boc-β-
alanine and the non-nucleophilic base triethylamine were added to the stirred solution. The 
mixture was stirred at room temperature and checked by TLC after about 15 min 
(DCM/MeOH, 8:2 + ninhydrin). Several new spots had formed on the TLC which indicated 
that a reaction had taken place. After about 1,5 hours of stirring, the spots of the starting 
material had vanished nearly completely. The clear solution was poured into ice-cold water 
and stirred vigorously. As no precipitate had formed, the water and the DMF were removed 
again under reduced pressure. The residue was slightly yellow colored oil. This residue was 
put on a silica-gel column for the isolation of two spots that were likely to be the desired 
product. DCM/MeOH (8:2) was used an eluent for the column. It was not possible to 
separate the spots completely, but in that way at least a certain level of purification could be 
reached.  
Two sets of fractions were collected, the solvent was removed and samples were given away 
for MS-analysis. In both cases the peaks did not correlate to the expected mass. The desired 
compound should have had a peak at a mass-to-charge ratio (m/z) of 376, whereas the 
sample-peaks appeared at m/z 741 and 570. We were unable to identify these peaks. 
3.4 Possible reasons for the synthetic difficulties occurring when the 
unprotected bis-homotris was introduced as a branching unit 
 
Initially, bis-homotris was utilized in various attempts as a tripodal branching to synthesize 
the main building block for the desired first generation dendrons. This molecule has already 
been described in the literature[40], but has not been applied for the direct use in dendrimer 
synthesis. During this project, a few different methods have been employed to accomplish an 
amide bond formation between the carboxylic acid of the protected β-alanine and the amine 
triol bis-homotris. As described earlier, none of these attempts had been successful or 
satisfying due to the unusual chemical properties of this molecule.  
Bis-homotris possesses hydroxyl groups and an amino group in a geometric proximity that 
allows the simultaneous formation of three intramolecular hydrogen bonds. It is likely that 
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the lone pair of the nitrogen in the amine group is attracted by the hydrogen atom in one of 
the hydroxyl groups and therefore forms an intramolecular hydrogen bond. Additionally, the 
two hydrogen atoms of the primary amine in bis-homotris are able to act as hydrogen bond 
donors for the oxygen lone pairs of the remaining two hydroxyl groups. If all the possible 
intramolecular hydrogen bonds are formed, the molecule is arranged in a highly symmetrical 
conformation. In the three dimensional picture of bis-homotris that is presented below 
(Figure 9), an energy minimizing performance visualized this interesting arrangement of 
intramolecular hydrogen bonds. This model was generated with the program ChemBio3D.  
 
Figure 9: Three dimensional model of an energy-minimized bis-homotris using ChemBio3D 
Assisted by Dr. XL Kong, the distances for these hydrogen bonds have been determined using 
the program mentioned above. The calculated lengths for the three presumably formed 
hydrogen bonds are stated in Å (angstrom) as follows: 
 
 N---HO  1,70 Å  
 NH---O  2,39 Å 
 NH---O  2,41 Å 
 
These three possible intramolecular hydrogen bonds and the steric conformation of the 
hydroxyl chains contribute to a decreased availability of the amino group during chemical 
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reactions. The three dimensional model also explains that the compound was not readily 
dissolving in various solvents. It is assumed that the closed, intramolecular hydrogen bond 
ring system predominates under conditions of chemical reactions. 
To circumvent these complications, protected derivatives were used in further synthetic 
schemes.   
3.5 Investigation of ditert-butyl 4-amino-4-(3-tert-butoxy-3-oxo-
propyl)heptanedioate as the tripodal branching unit 
 
Formula 7: New building block ditert-butyl 4-amino-4-(3-tert-butoxy-3-oxo-propyl)heptanedioate  
 
This new building block reagent (Formula 7) was provided by Tao Zhou who had prepared it 
following the procedure described by Newkome et al.[43]. Using the protected branching unit 
instead of the triol bis-homotris should help to circumvent the problem of a decreased 
availability of the amine group.  
3.5.1 Coupling of a tert-butyl ester - protected tripodal branching unit with the Fmoc – 
protected linking unit β-alanine followed by an attempt to reduce the protective 
tert-butyl esters 
DCC, HOBt
MW= 415,29 MW= 708,40
 
Scheme 15: Synthesis of ditert-butyl 4-(3-tert-butoxy-3-oxo-propyl)-4-[3-(9H-fluoren-9-
ylmethoxycarbonylamino)propanoylamino]heptanedioate using DCC and HOBt as coupling agents 
 
Applying peptide coupling procedures, Fmoc-β-alanine was treated with the amino ester, 
DCC and HOBt in anhydrous DMF and stirred at room temperature overnight. The precipitate 
was filtered off and the solvent was removed in vacuo to furnish orange colored oil. This 
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residue was passed through a silica gel column and white crystals were obtained as the 
desired compound (ditert-butyl 4-(3-tert-butoxy-3-oxo-propyl)-4-[3-(9H-fluoren-9-
ylmethoxycarbonylamino)propanoylamino]heptanedioate) in an excellent yield.  
MS analysis confirmed the presence of the coupling product with a peak at m/z 731,20 
([M+Na]+). 1H-NMR investigation lend further support for the correct compound when peaks 
deriving from the aromatic Fmoc group appeared at a range of 7,23-7,70 ppm. Additionally, 
the methyl groups were found as singlets at 1,36 and 1,37 ppm.  The IR spectrum of Boc-β-
Ala-OH was compared to the IR spectrum of the obtained compound and instead of one 
sharp N-H stretch at 3442 cm-1, two sharp N-H stretches could be observed at 3371 and 3313 
cm-1. 
The detailed synthetic procedure is described in section 5.6. 
 
Scheme 16: Attempt to reduce the tert-butyl esters using sodium borohydride (NaBH4) as reducing agent 
 
As shown in Scheme 16, it was then attempted to convert the tertiary butyl esters into 
alcohols using sodium borohydride as a reducing agent. The starting material, containing the 
three esters, was therefore dissolved in anhydrous tetrahydrofuran (THF) and heated under 
reflux at 70° C for one hour while solid sodium borohydride was added in small portions. 
When anhydrous MeOH was added dropwise, the solution stopped bubbling and cleared up. 
The reaction was checked by TLC and was judged to be complete after 1,5 hours. A solution 
of saturated ammonium chloride was added and white precipitate formed immediately. The 
mixture was left to stir for about 1,5 hours. The solution was then extracted with ethyl 
acetate and dried over sodium sulfate. Removing the solvent afforded a white, sticky residue 
in a high yield.  
The analysis of the data of the MS and the 1H-NMR spectrum revealed that instead of the 
desired triol, the compound shown in Formula 8 had formed. The 1H-NMR demonstrated the 
loss of the aromatic part of the molecule and in the MS spectrum a parental peak appeared 
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at m/z 487, which corresponds to the formula below. Apparently, the Fmoc-group was not 
sufficiently stable and the conditions led to the decomposition of the molecule.  
 
Formula 8: Product of the attempted reduction: Loss of the Fmoc-group 
3.5.2 Coupling of a tert-butyl ester - protected tripodal branching unit with the Boc – 
protected linking unit β-alanine followed by an attempt to reduce the protective 
tert-butyl esters 
DCC, HOBt
MW= 415,29 MW= 586,38
 
Scheme 17: Synthesis of ditert-butyl 4-[3-(tert-butoxycarbonylamino)propanoylamino]-4-(3-tert-butoxy-3-oxo-
propyl)heptanedioate using DCC and HOBt as coupling agents 
 
This time the coupling of the branching unit and the linking unit was carried out using a Boc-
protected β-alanine instead of the unstable Fmoc-group. As presented in Scheme 17, Boc-β-
alanine was treated with the amino ester, DCC and HOBt in anhydrous DMF and stirred at 
room temperature overnight. The precipitate was filtered off and the solvent was removed in 
vacuo to furnish red colored oil. This residue was passed through a silica gel column and 
white crystals were obtained as the desired compound (ditert-butyl 4-[3-(tert-
butoxycarbonylamino)propanoylamino]-4-(3-tert-butoxy-3-oxo-propyl)heptanedioate) in a 
good yield.  
MS analysis confirmed the presence of the coupling product with a peak at m/z 609,20 
([M+Na]+). 1H-NMR analysis showed one sharp singlet at 1,38 ppm deriving from the protons 
of all the methyl groups. The other peaks appeared as expected and could be easily assigned. 
The IR spectrum of Boc-β-Ala-OH was compared to the IR spectrum of the obtained 
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compound and instead of one sharp N-H stretch at 3442 cm-1, two sharp N-H stretches could 
be observed at 3389 and 3340 cm-1. 
The detailed synthetic procedure is described in section 5.7. 
 
Scheme 18: Attempt to reduce the tertiary butyl ester of Boc-Glu-OtBu using lithium aluminum hydride (LiAlH4) 
as reducing agent 
 
In the next step it was decided to use Boc-Glu-OtBu as a test molecule for the selective 
reduction of the tertiary butyl ester. If this reaction had been successful, the product of the 
previous step, ditert-butyl 4-[3-(tert-butoxycarbonylamino)propanoylamino]-4-(3-tert-
butoxy-3-oxo-propyl)heptanedioate, would have been reacted under the same conditions. 
Both the test molecule and the “real” compound possess a Boc group protecting an amine 
and a tertiary butyl ester and are therefore comparable in their chemical behavior.  
 The reaction shown in Scheme 18 was carried out in various conditions, but no 
attempt led to the desired product. In the first attempt lithium aluminum hydride (1M 
solution in THF) was added to a solution of Boc-Glu-OtBu in anhydrous THF, stirred at 0°C for 
two hours and then treated with diluted HCl. The solvent (THF) was removed under reduced 
pressure and remaining the aqueous phase was washed with ethyl acetate. The residue of 
the organic phase was analyzed by 1H-NMR and MS. The desired product had not been 
found, but a lot of starting material was still present. 
 In other attempts Boc-Glu-OtBu was added in small portions to the solution of LiAlH4 
in THF and the temperature was increased constantly until it was refluxed for one hour. 
Monitoring the reaction by TLC showed that a new spot had formed at the bottom of the 
plate. In the MS spectrum of the isolated fraction a parental peak appeared at m/z 333, 
which does not correspond to the desired product.  
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3.6 Synthesis of tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate in four steps 
using [7-acetoxy-4-(3-acetoxypropyl)-4-amino-heptyl] acetate as the 
tripodal building block 
1 2
3 4
 
Scheme 19: Overall scheme for the synthesis of tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate in four steps 
 
For the reasons explained earlier it was decided not to proceed with the unprotected bis-
homotris, but to use the easily obtained triacetate of nitromethane-tris-propanol, [7-
acetoxy-4-(3-acetoxypropyl)-4-nitro-heptyl] acetate 1, as presented in Scheme 19. Catalytical 
reduction afforded the corresponding amine 2, which was then easily coupled to Boc-β-
alanine. The resulting compound, [7-acetoxy-4-(3-acetoxypropyl)-4-[3-(tert-
butoxycarbonylamino)propanoylamino]heptyl] acetate 3 was converted into the triol 4 
through a high-yielded transesterification. In this way it was possible to prepare the building 
block for the desired HPO containing dendron in four steps with a high overall yield. The 
preparation of the new building block [7-acetoxy-4-(3-acetoxypropyl)-4-amino-heptyl] 
acetate 2 had been prepared following the procedures described by Newkome et al.[43] 
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3.6.1 Protection of nitromethane-tris-propanol through the formation of a triacetate: 
Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-nitro-heptyl] acetate 
MW= 235,29 MW= 361,17
pyridine
 
Scheme 20: Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-nitro-heptyl] acetate with acetic anhydride in 
pyridine 
 
In the first step, as shown in Scheme 20, the starting material nitromethane-tris-propanol 
was suspended in acetic anhydride and was stirred at 70°C together with pyridine for 12 
hours. The reaction was judged to be complete when the TLC analysis showed all the 
ninhydrin-sensitive starting material to have disappeared. A new spot that could be detected 
with iodine dye had formed and indicated a clean reaction. The reaction solution was 
allowed to cool to room temperature and quenched by stirring it with water. After the 
neutralization with solid sodium hydrogen carbonate and extraction with diethyl ether the 
organic phase was washed with brine. The solvent and pyridine were removed under 
reduced pressure and the triacetate was obtained in a good yield as yellow oil. 
Along with MS analysis, the structure was also determined by 1H-NMR analysis. The 
transformation of the triol into the triacetate was confirmed by the presence of a singlet 
peak at δ 2 ppm that corresponds to the 9 protons of the three acetate methyl groups. 
The detailed synthetic procedure is described in section 5.8. 
3.6.2 Reduction of the nitro group:  
Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-amino-heptyl] acetate 
MW= 361,17 MW= 331,20
H2
Raney nickel
 
Scheme 21: Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-amino-heptyl] acetate using Raney nickel as reducing 
agent 
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For the reduction of the nitro group (Scheme 21), the commercially available catalyst Raney 
nickel slurry in water was washed with EtOH and then added to a solution of [7-acetoxy-4-(3-
acetoxypropyl)-4-nitro-heptyl] acetate in EtOH. The mixture was hydrogenated at 40 pound-
force per square inch (psi). When the hydrogen uptake ceased after approximately 24 hours, 
the Raney nickel was carefully filtered off and the solvent was removed in vacuo. Slightly 
yellow oil was obtained and a brightly red, ninhydrin-sensitive spot on the TLC was then 
isolated by silica gel column chromatography. As a residue, slightly yellow coloured oil was 
obtained in a good yield. 
The transformation of the nitro group into the amino group was confirmed by a 1H-NMR 
spectrum. In the 1H-NMR data for the starting material, the 6 protons of the methylene 
groups adjacent to the quaternary carbon atom showed a signal at δ 1,91-1,95 ppm, whereas 
in the amino-compound an upfield shift of these protons to δ 1,29-1,34 ppm could be 
observed. This is due to the fact, that the new amino group is less electronegative and has a 
less deshielding effect on the surrounding atoms.  Furthermore the identity was proven also 
by MS analysis and infrared (IR) investigation. In the IR spectrum, the N-H stretches of the 
primary amine could be observed at a broad band around 3368 cm-1, whereas the C=O 
stretching bands appeared at 1736 cm-1. Bands for N-O stretches could not be found and 
supported the presence of the amino group in the molecule.  
The detailed synthetic procedure is described in section 5.9. 
3.6.3 Amide coupling with Boc- β-alanine:  
Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-[3-(tert-
butoxycarbonylamino)propanoylamino]heptyl] acetate 
DCC, HOBt
MW= 331,2 MW=502,29
 
Scheme 22: Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-[3-(tert-
butoxycarbonylamino)propanoylamino]heptyl] acetate using the coupling agents DCC and HOBt 
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Boc-β-alanine and the previously synthesized amine (Scheme 22) were treated with DCC and 
HOBt in anhydrous DMF at 25 °C for approximately 24 hours. After the filtration of DCU and 
the removal of the solvent, the sticky residue was dissolved in DCM and subsequently 
washed with HCl, water and NaHCO3. The HCl helped to get rid of the remaining HOBt while 
washing the organic phase with water and NaHCO3 realized a further removal of ninhydrin-
sensitive impurities with retention factors below the suspected compound-spot. Passing the 
concentrated residue of the organic phase through a silica gel column afforded the isolation 
of the desired spot on the TLC and white crystals were obtained in a very good yield.  
 The identity of this compound was confirmed by MS analysis, IR analysis and also by 
the investigation of the 1H-NMR spectrum. The absorptions of all the protons in the molecule 
could be easily assigned. There was a sharp peak for the CH3 groups of the protective Boc-
group (1,36 ppm) as well as for the methyl groups of the three acetates (1,98 ppm). In the IR 
spectrum it was possible to see the a sharp N-H stretching band deriving from the amide at 
3287 cm-1 and the C=O stretching bands from both the carbamate and the amide at 1641 cm-
1 and 1684 cm-1.  
The detailed synthetic procedure is described in section 5.10. 
3.6.4 Saponification of the triacetate:  
Synthesis of tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-hydroxypropyl)butyl]amino]-3-
oxo-propyl]carbamate 
 
MW= 502,29 MW= 576,26
K2CO3
EtOH
 
Scheme 23: Transesterification in EtOH: synthesis of tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate 
 
Scheme 23 demonstrates the conversion of the triacetate into the corresponding triol via 
transesterification in EtOH. The triacetate was dissolved in EtOH and stirred with potassium 
carbonate at 30 °C for 18 hours. TLC analysis revealed that all the iodine sensitive starting 
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material had disappeared and that a new, both iodine and ninhydrin sensitive spot had 
appeared at the bottom of the TLC plate. Upon removal of the fine precipitate that had 
formed during the reaction, the solution was concentrated in vacuo and the triol was 
obtained quantitatively as viscous, white oil. The triol possesses extremely hygroscopic 
characteristics and had to be stored in a high vacuum desiccator for a few days to solidify 
completely. 
Having determined the structure by 1H-NMR analysis, MS and IR analysis lend further 
support for the identity of the desired compound. In the 1H-NMR data the loss of the acetate 
signals could be observed together with an upfield shift of the CH2OH triplet to 3,32-3,33 
ppm (from 3,95-3,98 ppm for CH2OAc). The IR spectrum showed an intense, broad O-H 
stretching band from 3500 to 3300 cm-1 and the lack of a sharp C=O absorption stretching 
band which had appeared at 1738 cm-1 in the triacetate. 
The detailed synthetic procedure is described in section 5.11. 
3.7 Attempt to complete the dendron by coupling one type of HPO-
derivative to the successfully established triol-branching unit 
N2
DCC, DMAP
n= 5
 
Scheme 24: Attempt of coupling the HPO derivatives to the triol using DCC and DMAP under N2 atmosphere 
 
For the last step of the completion of the desired dendron it was necessary to couple one 
type of the previously synthesized HPO-derivatives to the triol-branching unit (prepared 
according to section 3.6.4.).  
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As shown in Scheme 24, 3-benzyloxy-1-carboxypentyl-2-ethyl-4(1H)-pyridinone and DCC 
were dissolved in DCM/DMF (1:1) under a nitrogen atmosphere and stirred for 30 min at 
room temperature. At this point it was already possible to observe DCU that had precipitated 
from the solution. A precipitation of DCU before the addition of the triol therefore indicated 
an undesired side reaction. The triol, which had been dissolved in DMF, was added dropwise 
with a syringe over a period of another 30 min. DMAP (dissolved in DMF) was added with a 
syringe and the solution was left to stir at room temperature for 24 hours and then allowed 
to cool down in the fridge. DCU was filtered off and the solvent was removed in vacuo.  
TLC analysis (9 DCM: 1MeOH) revealed a new spot that was visible under UV-light and 
sensitive for both ninhydrin and iodine dye. This indicated the presence of the desired 
compound and suggested a successful reaction.  
The residue of this reaction was put on a column and eluted with DCM/MeOH (9:1). The 
separation of the desired spot from other impurities could not be fully achieved and it was 
also found that the original spot had split in three individual and very close spots.  
A sample of the fractions containing these close spots had been analyzed by electrospray 
ionization (ESI)-MS. In the spectrum displayed in Figure 10 it was found that there were 
traces of the desired compound present at m/z 1352,83 [M+H]+ together with incompletely 
coupled dendrons at m/z 702,50 and m/z 1027,67.   
 
Figure 10: ESI-MS analysis of the described reaction: presence of the desired compound and incomplete 
coupling products; x-axis: m/z, y-axis: relative abundance 
 
 
46  Instrumental details and equipment 
4 Instrumental details and equipment 
 
NMR 
Nuclear magnetic resonance spectra were recorded using a Bruker 400 (400 MHz) NMR 
spectrometer. Chemical shifts (δ) are reported in ppm downfield from the internal standard 
tetramethylsilane (Me4Si, δ=0). The resonance patterns are given with the notations s 
(singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). A broad signal is indicated by 
the notation br. The samples were prepared by dissolving 5-7 mg of the compound in 0,5 ml 
deuterated solvent (CDCl3 or DMSO). The data ejected from the spectrometer was analyzed 
using the software NMRNotebook (NMRTEC). 
Mass spectrometry 
Mass spectrometry was performed by using a ThermoScientific LCQ Deca XP (electro-spray 
ionization, ESI) spectrometer. The procedure was carried out by the Centre of Excellence for 
Mass Spectrometry (CEMS) at King's College London. Samples were prepared by dissolving 1 
mg of the compound in 1 mL of MeOH or other suitable solvents.  
Melting points 
Melting points were determined on an Electrothermal IA 9100 Melting Point Apparatus and 
are uncorrected.  
Chromatography 
Thin layer chromatography was carried out using classical aluminum plates coated with silica 
gel 60 F254 from Merck. When column chromatography was applied, silica gel 40-63 µm 
(Zeoprep) from Zeochem was used.  
Chemicals 
All the reagents and solvents were purchased from Sigma-Aldrich, BDH, Alfa-Aesar and 
Fischer Scientific in either reagent or analytical grade and used without further purification. 
 
Synthetic procedures 47 
5 Synthetic procedures 
5.1 Synthesis of 3-benzyloxy-2-ethyl-pyran-4-one 
 
Ethyl-maltol (115,51 g, 825,07 mmol) was placed in a one-neck round bottomed flask and 
dissolved in 400 mL of MeOH. A solution of NaOH (36,3 g in 100 mL of water) was added and 
the flask was equipped with a magnetic stirrer. Benzyl chloride (113,41 mL, 990,08 mmol) 
was placed in an addition funnel and added dropwise to the stirred solution. The bath 
temperature was brought to 100° and allowed to react under reflux overnight. After 18 hours 
of reflux the clear solution had turned orange. The completion of the reaction was checked 
by TLC (DCM/MeOH 9,5:0,5). The solvent (MeOH) was removed under reduced pressure. 
DCM (500 mL) was added to the residue and placed in a separating funnel. First, the solution 
was washed with NaOH 5% (3 x 250 mL) and saturated sodium chloride solution (1 x 250 mL) 
and then with water (1 x 300 mL). A change of color from brown to yellow to deep red was 
observed. The organic phase was dried over sodium sulfate. After having filtered off the 
sodium sulfate, the solvent was removed under reduced pressure. The residue was dissolved 
in 50 mL of diethyl ether. The flask was put in the freezer overnight, but no crystals had 
formed until the next day. Upon scratching the walls of the flask with a glass rod, the 
compound started to precipitate from the solution. The crystals were filtered off through a 
Büchner funnel and washed with an ice-cold mixture of hexane/diethyl ether.  
 
Yield:    124,62 g (65,60%) nearly colourless needles 
 
Melting point: 95° C 
1H-NMR (CDCl3): δ 0,90-0,94 (t, -CH2CH3, 3 H); 2,41-2,47 (q, -CH2CH3, 2 H); 5,10 (s, -
 0CH2-, 2 H); 6,29-6,30 (d, 5-H , 1 H); 7,24-7,33 (m, -Phe, 5 H); 7,55-7,57 
 (d, 6-H, 1 H) 
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5.2 Synthesis of 3-Benzyloxy-1-carboxypentyl-2-methyl-4(1H)-
pyridinone 
 
2-Ethyl-3-benzyloxy-4-pyranone (5 g, 21,74 mmol) and 6-aminocaproic acid (8,56 g, 65,22 
mmol) were placed in a one-neck round bottomed flask and dissolved in a mixture of EtOH 
and water (50:50). The flask was equipped with a magnetic stirrer and 10 N NaOH was added 
until a pH of 13 was reached. The solution was heated under reflux at 100° overnight. TLC 
analysis (DCM/MeOH 9,5:0,5) showed the reaction to be completed. The solvent (EtOH) was 
removed under reduced pressure and the remaining solution was acidified with HCl to pH 4 
to achieve precipitation. The aqueous solution was washed with DCM (3 x 100 mL) and the 
combined organic extracts were dried over sodium sulfate. Sodium sulfate was filtered off 
and the solvent (DCM) was removed under reduced pressure. A viscous orange/brown liquid 
was obtained. The residue was dissolved in a small amount of EtOH and then diethyl ether 
was added until the solution went cloudy. The mixture was allowed to stand in the fridge 
overnight. The precipitate was collected on a Büchner funnel and washed with several small 
portions of diethyl ether. Yellow/brown crystals were obtained.  
 
Yield:    5,16 g (69,14%) yellow/brown crystals 
 
1H-NMR (CDCl3):  δ 1,04-1,07 (t, -CH2CH3, 3 H); 1,36-1,42 (m, -CH2-CH2-CO-, 2 H); 1,65-
   1,73 (m, N-CH2-CH2-CH2-, 4 H); 2,36-2,40 (t, N-CH2-, 2 H); 2,58-2,63 (q, -
   CH2CH3, 2 H); 3,84-3,87 (t, -CH2-CO-, 2 H); 5,26 (s, -O-CH2-, 2 H); 6,68-
   6,70 (d, 5-H, 1 H); 7,29-7,39 (m, -Phe, 5 H); 7,41-7,43 (d, 6-H, 1 H), 9,96 
   (br s, -OH, 1 H) 
MS (ESI) m/z:   344,13 [M+H]+  
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5.3 Synthesis of 3-Benzyloxy-1-carboxyheptyl-2-methyl-4(1H)-
pyridinone 
 
2-Ethyl-3-benzyloxy-4-pyranone (1,15 g, 5 mmol) and 8-aminooctanoic acid (1,59 g, 10 
mmol) were placed in a one-neck round bottomed flask and dissolved in a mixture of EtOH 
and water (50:50, 8 mL). The flask was equipped with a magnetic stirrer and 1 M NaOH (0,4 
g, 10 mmol) was added. Upon this, the content of the flask turned bright yellow, but not all 
the solid parts of the starting material dissolved at once. The solution was heated under 
reflux at 100° for 48 hours. TLC analysis (DCM/MeOH 9:1) showed the reaction to be 
completed as all the starting material had disappeared. The reaction mixture was cooled to 
room temperature and 6 M HCl was added until a pH value of 8 was reached. EtOH was 
removed under reduced pressure and the remaining aqueous solution was washed with 
DCM (3 x 25 mL). The aqueous phase was again acidified with 10% citric acid to achieve the 
precipitation of 3-benzyloxy-1-carboxyheptyl-2-methyl-4(1H)-pyridinone. The precipitation 
started at a pH value of around 6,5 and lasted until pH 3 was reached. The resulting solid 
was filtered off and dissolved in DCM (100 mL). The organic phase was washed with 
saturated sodium chloride (brine) and dried over anhydrous sodium sulfate. Upon removal 
of the solvent, pale white crystals were obtained. 
 
Yield:    1,38 g (75,34 %) pale, white crystals 
 
1H-NMR (CDCl3):  δ 0,95-0,98 (t, -CH2CH3, 3 H); 1,17-1,27 (m, -CH2-CH2 -CH2-CH2-CO, 6 H); 
   1,54-1,60 (m, N-CH2-CH2-CH2-, 4 H); 2,25-2,29 (t, -N-CH2-, 2 H); 2,48-
   2,54 (q, -CH2CH3, 2 H); 3,58-3,72 (t, -CH2-CO-, 2 H); 5,19 (s, -O-CH2-, 2 
   H); 6,56-6,58 (d, 5-H, 1 H); 7,15-7,27 (m, -Phe, 5 H); 7,33-7,36 (d, 6-H, 1 
   H), 9,97 (br s, -OH, 1 H) 
MS (ESI) m/z:  372,13 [M+H]+ 
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5.4 Synthesis of 4-amino-4-(3-hydroxypropyl)-1,7-heptanediol  
(Bis-homotris) 
5.4.1 Synthesis of Bis-homotris using Zn/HCl as reducing agents 
 
Nitromethane-tris-propanol (5 g, 21,25 mmol) was dissolved in 100 mL EtOH. The reaction 
was started at room temperature and while 6M HCl (75 mL) was added dropwise, 16,5 g of 
zinc powder was added in portions. The bath temperature was slowly increased to 60°C and 
after the initiation of the reaction the mixture was stirred at reflux for two hours.   
After having checked the reaction by TLC (DCM/MeOH 9:1), the solution was filtered in order 
to remove the zinc powder. EtOH was evaporated under reduced pressure and the residue, a 
clear liquid, was dissolved in ethyl acetate (150 mL). This solution was washed with 2M 
sodium bicarbonate (300 mL). While adding the base, the aqueous phase turned white and 
creamy, at the same time bubbles of gas were welling up. Furthermore, solid potassium 
carbonate was added to the two phases. The white precipitate in the aqueous phase was 
filtered off; the ethyl acetate phase was separated from the aqueous phase and then 
evaporated under reduced pressure. As there was no residue found, it was obvious, that the 
compound had to be in the present in the aqueous phase.  
 The presence of amino groups in the water phase was checked with a solution of 
ninhydrin (1,5 g ninhydrin, 50 mL butanol, 3 mL acetic acid) an a TLC plate. The purple spots 
indicated the presence of amino groups. The water was evaporated under reduced pressure 
and dried in the vacuum drier. Then the residue was dissolved in MeOH. The solution was 
filtered in order to remove the excessive inorganic salt. The solvent (MeOH) was evaporated 
under reduced pressure, but there was still a lot of salt present.  
 The residue was dissolved in anhydrous  isopropanol and then filtered through a 
sintered glass funnel to remove the excessive salt. Under reduced pressure the solvent was 
evaporated and a sticky yellow oil was obtained.  
 
Yield of crude product:  2,88 g (66,07%) yellow sticky oil 
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5.4.2 Synthesis of Bis-homotris using Raney nickel as reducing agent 
 
Nitromethane-tris-propanol (2,5 g, 10,6 mmol) was dissolved in 60 mL of EtOH. T-1[41] Raney 
nickel (6 g) was added and hydrogenation was carried out at 40 psi. The reaction was 
completed within 24 hours. The Raney nickel was filtered off and the solvent was removed 
under reduced pressure. A yellow sticky oil was obtained. 
 
Yield:    1,68 g (0,76,74%) slightly yellow sticky oil 
 
1H-NMR (DMSO):  δ 1,21-1,25 (m, -CH2-CH2 -CH2-OH, 6 H); 1,33-1,41 (m, -CH2-CH2 -CH2-
   OH, 6 H); 3,30-3,36 (m, -CH2-CH2 -CH2-OH, 6 H) 
MS (ESI) m/z:  206,07 [M+H]+ 
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5.5 Synthesis of ((2,5-dioxopyrrolidin-1-yl) 3-(tert-
butoxycarbonylamino)propanoate 
 
Boc-β-Alanine (1 g, 5,28 mmol) and N-hydroxysuccinimide (0,61 g, 5,28 mmol) were 
dissolved in ethyl acetate (25 mL, dried over sodium sulfate). DCC (1,1 g, 5,28 mmol) in ethyl 
acetate (4 mL) was added to the stirred solution. The mixture was stirred at room 
temperature overnight and then stored in the fridge for a couple of hours to precipitate as 
much DCU as possible. The heavy white precipitate was filtered off and the filter cake was 
washed with cold ethyl acetate. The combined filtrates were concentrated and crystals 
formed at room temperature. Propan-2-ol (approximately 3 mL) was added and more 
crystals formed. The precipitate was allowed to stand in the fridge overnight and then 
filtered off and washed with cold propan-2-ol. White crystals were obtained.  
 
Yield:    1,2 g (80%) white crystals 
 
Melting point: 95° C 
1H-NMR (CDCl3):  δ 1,38 (s, -CH3, 9 H); 2,76-2,78 (m, -CH2-COO-N< and –CH2-succinimide, 
   6 H); 3,43-3,48 (q, t-Bu-OOC-NH-CH2-, 2 H); 5,04 (s, -NH-, 1 H) 
IR (KBr):  3362, 2978, 2934, 1824, 1779, 1688, 1523, 1435, 1366, 1289,  
   1198, 1096 cm-1 
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5.6 Synthesis of  
ditert-butyl 4-(3-tert-butoxy-3-oxo-propyl)-4-[3-(9H-fluoren-9-
ylmethoxycarbonylamino)propanoylamino]heptanedioate  
 
Ditert-butyl 4-amino-4-(3-tert-butoxy-3-oxo-propyl)heptanedioate (2,45 g, 6 mmol), Fmoc-β-
alanine (1,63 g, 5 mmol), DCC (1,24 g, 6 mmol) and HOBt (0,81 g, 6 mmol) were dissolved in 
dimethylformamide (DMF) (25 mL) and placed in a one-neck round-bottomed flask. The 
solution was stirred at room temperature overnight. The solution turned slightly pink and 
contained white, solid DCU. The reaction was judged complete by TLC (DCM/MeOH 9:1). The 
white precipitate was filtered through a Büchner funnel and then the solvent (DMF) was 
removed under reduced pressure. Orange colored oil was obtained. The residue was 
dissolved in ethyl acetate and was then passed through a silica gel column in order to purify 
the compound. The column was eluted with ethyl acetate/hexane (1:3, increased to 1:1). 
Having removed the solvent of the collected fractions, white crystals were obtained.  
 
Yield:    3,48 g (98,30%) white crystals  
 
1H-NMR (CDCl3):  δ 1,36 (s, -CH3, 18 H); 1,37 (s, -CH3, 9 H); 1,89-1,93 (m, -CH2-CH2 –COO-, 
   6 H); 2,12-2,16 (m, -CH2-CH2 –COO-, 6 H); 2,29-2,33 (m, -CH2-COO-NH-
   C, 2 H); 3,41 (t, -Fmoc-NH-CH2-, 2 H); 4,14-4,15 (m, 9-H Fmoc, 1 H); 
   4,29 (d, -CH2-OOC-NH-, 2 H); 7,24 (m, 2-H and 7-H Fmoc, 2 H); 7,31-
   7,34 (m, 3-H and 6-H Fmoc, 2 H); 7,52-7,54 (d, 1-H and 8-H Fmoc, 2 H); 
   7,68-7,70 (d, 4-H and 5-H Fmoc, 2 H) 
IR (KBr):  3371, 3313, 2976, 1722, 1688, 1662, 1535, 1450, 1245, 1153,  
   1105 cm-1 
MS (ESI) m/z:  731, 20 [M+Na]+ 
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5.7 Synthesis of ditert-butyl 4-[3-(tert-
butoxycarbonylamino)propanoylamino]-4-(3-tert-butoxy-3-oxo-
propyl)heptanedioate 
 
Ditert-butyl 4-amino-4-(3-tert-butoxy-3-oxo-propyl)heptanedioate (1, 25 g, 3 mmol), Boc-β-
alanine (0,57 g, 3 mmol), DCC (0,62 g, 3 mmol) and HOBt (0,41 g, 3mmol) were dissolved in 
DMF (20 mL) and placed in a one-neck round-bottomed flask. The solution was stirred at 
room temperature for 48 hours. The solution turned pink and contained white, solid 
precipitate (DCU). The reaction was judged complete by TLC (DCM/MeOH 9:1, iodine and 
ninhydrin dyes were used). The white precipitate was filtered through a Büchner funnel and 
then the solvent (DMF) was removed under reduced pressure. Red colored oil was obtained. 
The residue was dissolved in ethyl acetate and was then passed through a silica gel column in 
order to purify the compound. The column was eluted with ethyl acetate/hexane (1:1). 
Having removed the solvent of the collected fractions, white crystals were obtained.  
 
Yield:    1,35 g (76,76%) white crystals 
 
1H-NMR (CDCl3):  δ 1,37 (s, -CH3, 36 H); 1,88-1,92 (t, -CH2-CH2-COO-tBu, 6 H); 2,12-2,16 
   (t, -CH2-CH2-COO-tBu, 6 H); 2,25-2,27 (t, -CH2-CO-NH-, 2 H);  3,27- 
   3,32 (q, -OOC-NH-CH2-, 2 H);  
IR (KBr):  3389, 3340, 2985, 1730, 1695, 1649, 1544, 1524, 1367, 1253 cm-1 
MS (ESI) m/z:  609,20 [M+Na]+ 
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5.8 Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-nitro-heptyl] acetate 
 
Nitromethane-tris-propanol (2g, 8,5 mmol) was placed in a one-neck round bottomed flask 
and suspended in acetic anhydride (6,8 mL, 72,3 mmol). The mixture (nitromethane-tris-
propanol did not dissolve completely at room temperature) was stirred and pyridine (0,07 
mL, 0,85 mmol) was added. The solution was heated to 70 °C for 12 hours (during this time 
the nitromethane-tris-propanol dissolved completely) and a clear and yellow solution was 
obtained. The reaction was monitored by TLC (DCM/MeOH, 9:1) and judged to be completed 
when all the starting material had gone.  After the heating, the flask was allowed to cool 
down to room temperature and poured into water (40 mL). The solution was stirred for three 
hours in order to quench the reaction. Sodium hydrogen carbonate was added as a solid to 
the stirred solution until a neutral pH value was reached. The oily yellow phase was extracted 
from the aqueous phase by extraction with ether (3x25 mL). The combined organic extract 
was washed with a solution of saturated sodium chloride and then dried over anhydrous 
sodium sulfate. The solvent and the remaining pyridine were removed under reduced 
pressure to afford the triacetate as yellow oil. 
 
Yield:    2,72 g (70,23%) yellow oil 
 
1H-NMR (CDCl3):  δ 1,46-1,53 (m, -CH2-CH2-CH2-OAc, 6 H); 1,91-1,95 (m, -CH2-CH2- CH2-
   OAc, 6 H); 2 (s, -CH3, 9 H); 3,99-4,02 (t, -CH2-CH2-CH2-OAc, 6 H) 
MS (ESI) m/z:  384,00 [M+Na]+ 
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5.9 Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-amino-heptyl] acetate 
 
Commercially available raney nickel slurry in water (5 g) was washed with EtOH and then 
added to a solution of [7-acetoxy-4-(3-acetoxypropyl)-4-nitro-heptyl] acetate (2,72 g, 7,53 
mmol) in EtOH (55 mL) and hydrogenated at 40 psi. After the hydrogen uptake had ceased 
(approximately 24 hours) the Raney nickel was carefully filtered off and the solvent was 
removed in vacuo. A slightly yellow oil was obtained (2,3 g, 92%) which was then purified by 
silica gel column chromatography using DCM/MeOH (8,5:2,5) as eluent. The residue was a 
slightly yellow oil. 
 
Yield:   1,7 g (70,88%) slightly yellow oil 
 
1H-NMR (CDCl3):  δ 1,29-1,34 (m, -CH2-CH2-CH2-OAc, 6 H); 1,51-1,57 (m, -CH2-CH2- CH2-
   OAc, 6 H); 1,98 (s, -CH3, 9 H); 3,98-4,01 (t, -CH2-CH2-CH2-OAc, 6 H) 
IR:   3368, 2955, 1736, 1455, 1365, 1242, 1036 cm-1 
MS (ESI) m/z:  332,00 [M+H]+ 
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5.10 Synthesis of [7-acetoxy-4-(3-acetoxypropyl)-4-[3-(tert-
butoxycarbonylamino)propanoylamino]heptyl] acetate 
 
Boc-β-Alanine (0,99 g, 5,28 mmol) and [7-acetoxy-4-(3-acetoxypropyl)-4-amino-heptyl] 
acetate (1,75 g, 5,28 mmol) were placed in a one-neck round bottomed flask and dissolved in 
anhydrous DMF (20 mL). DCC (1,09 g, 5,28 mmol) and HOBt (0,71 g, 5,28 mmol) were added 
and the solution was stirred at 25 °C overnight. Precipitate formed after approximately 15 
min and the solution turned slightly yellow. The reaction was monitored by TLC (ethyl 
acetate/hexane 1:1) and judged to be complete after 24 hours. The dicyclohexylurea was 
filtered through Celite and the remaining solution was concentrated in vacuo to give a sticky 
yellow oil. This residue was dissolved in DCM (60 mL) and sequentially washed with cold 
aqueous 10% HCl (30 mL), water (30 mL), aqueous 10% NaHCO3 (30 mL) and a solution of 
saturated NaCL (30 mL). The organic phase was dried over anhydrous sodium sulfate and the 
solvent was removed under reduced pressure. A thick, viscous residue was obtained. For 
further purification, the residue was passed through a silica gel column, eluting with ethyl 
acetate/hexane (1:1). The polarity of the solvent was increased by using only ethyl acetate. 
White crystals were obtained. 
 
Yield:    2,2 g (83,02%) white crystals  
Melting point:   90° C 
1H-NMR (CDCl3):   δ 1,36 (s, (CH3)3-C-OOC-, 9 H); 1,47-1,48 (m, -CH2-CH2-CH2-OAc, 
    6 H); 1,65-1,66 (m, -CH2-CH2-CH2-OAc, 6 H); 1,98 (s, -O-OC-CH3, 
    9 H); 2,28-2,29 (t, -CH2-CO-NH-, 2 H);  3,27-3,29 (q, -OOC-NH-
    CH2-, 2 H); 3,95-3,98 (t, -CH2-CH2-CH2-OAc, 6 H) 
IR (KBr):   3287, 2979, 1738, 1684, 1642, 1545, 1385, 1367, 1243,  
    1174, 1051 cm-1 
MS (ESI) m/z:   525,25 [M+Na]+ 
58  Synthetic procedures 
5.11 Synthesis of tert-butyl N-[3-[[4-hydroxy-1,1-bis(3-
hydroxypropyl)butyl]amino]-3-oxo-propyl]carbamate 
 
A mixture of the triacetate (2,17 g, 4,3 mmol) and anhydrous potassium carbonate (0,19 g, 
1,4 mmol) was placed in a one-neck round bottomed flask and dissolved in absolute EtOH 
(27 mL). The solution was stirred at 30 °C for 18 hours and monitored by TLC, using ethyl 
acetate as eluent. The spots were revealed by both iodine and ninhydrin dye. The potassium 
carbonate dissolved only very slowly and even after 18 hours there was still some solid left. 
When all the starting material had gone, the fine precipitate that had formed was filtered 
through Celite and the solvent was reduced in vacuo. The residue was viscous, white oil that 
solidified when it was stored in a high vacuum desiccator.  
 
Yield:    1,59 g (98,15%) white solid 
1H-NMR (CDCl3):  δ 1,25-1,33 (m, -CH2-CH2-CH2-OH, 6 H); 1,37 (s, (CH3)3-C-OOC-, 9 H); 
   1,53-1,58 (m, -CH2-CH2-CH2-OH, 6 H); 2,18-2,21 (t, -CH2-CO-NH-, 2 H);  
   3,04-3,09 (q, -OOC-NH-CH2-, 2 H); 3,32-3,33 (t, -CH2-CH2-CH2-OH, 6 H) 
IR (KBr):  3500-3000, 3329, 2940, 1693, 1548, 1367, 1252, 1170, 1054 cm-1 
MS (ESI) m/z:  399,25 [M+Na]+ 
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6 Short summary of the synthetic achievements and 
outlook on further steps 
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Scheme 25: Synthesis of the HPO-derivatives 
 
Scheme 25 shows the synthetic pathway for the two benzyl-protected HPO-derivatives. 
Avoiding column chromatography, compound B1 and B2 could be synthesized by precipitation 
from solution in good yields.  
In further synthetic procedures it was initially attempted to prepare the triol building block 4 
(Scheme 26) from coupling unprotected bis-homotris to Boc-β-Ala-OH or Fmoc-β-Ala-OH. 
When these approaches failed, the tertiary butyl-ester protected branching unit was 
successfully coupled with both Boc-β-Ala-OH and Fmoc-β-Ala-OH. Since the removal of the 
esters did not work in both cases, it was decided to introduce another protective group for 
the triol branching unit.  
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Scheme 26: Synthetic Pathway for the synthesis of the triol 4 in four steps 
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Scheme 26 illustrates the pathway that leads to the desired triol building block 4 in four 
steps. The introduction of the acetate esters (1) turned out to be a convenient method for 
the protection of the triol. Hydrogenation of the nitro group (2), coupling with the linking 
unit Boc-β-Ala-OH (3) and saponification of the triacetate (4) were easily achieved in a 
relatively high overall yield. 
Due to the limited time that was available for my project, it was not possible to completely 
finish the desired dendron (compound 5, Scheme 27). The first attempt to couple the HPO-
derivative B1 to the triol building block 4 was only partially successful.  
N2
DCC, DMAP
n= 5, 6
5
B4
  
Scheme 27: Synthesis of the dendron: the last step using DCC and DMAP under a nitrogen atmosphere 
 
It is still necessary to work on the conditions of this procedure (Scheme 27) in order to 
achieve a more quantitative reaction. A chemist of the department of Medicinal Chemistry at 
KCL will carry on improving this last reaction with the aim of obtaining both of the desired 
dendrons in an acceptable yield and purity.  
Thus, the successful development of the previously described, convenient 4-step synthetic 
pathway will facilitate the synthesis of similar dendrons bearing more generations or other 
terminal groups. All of these compounds will be tested in biological essays for their suitability 
in photodynamic therapy. 
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1H-NMR    1H - nuclear magnetic resonance  
Å     angstrom 
ALA / 5-ALA    5-aminolevulinic acid 
aminocaproic acid   6-aminohexanoic acid 
bis-homotris    4-amino-4-(3-hydroxypropyl)-1,7-heptanediol 
Boc     tert-butyloxycarbonyl 
CoA     Coenzyme A 
CP94     1,2-diethyl-3-hydroxypyridin-4-one 
DCC     N,N’-dicyclohexyl-carbodiimide 
DCM     dichloromethane 
DCU     dicyclohexylurea 
DMF     dimethylformamide 
DMSO     dimethyl sulfoxide 
EEDQ     2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 
EPR     enhanced permeation and retention 
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ethyl maltol    2-ethyl-3-hydroxy-pyran-4-one 
EtOH     ethanol 
Fmoc     fluorenylmethyloxycarbonyl 
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HOBt     1-hydroxy-benzotriazole hydrate 
HpD     Haematoporphyrin derivative 
HPO     3-hydroxypyridin-4-one 
IR     infrared 
KBr     potassium bromide 
KCL     King’s College London 
K2CO3     potassium carbonate 
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kg     kilogram 
LiAlH4     lithium aluminum hydride 
MeOH     methanol 
Me4Si     tetramethylsilane 
mg     milligram  
MHz     megahertz  
mL     milliliter 
mmol     millimole   
MRI     magnetic resonance imaging 
MS     mass spectrometry 
MW     molecular weight 
m/z     mass-to-charge ratio 
NaHCO3    sodium hydrogen carbonate 
NaOH     sodium hydroxide   
nitromethane-tris-propanol  4-(3-hydroxypropyl)-4-nitro-1,7-heptanediol 
PBG     porphobilinogen 
PBGD     porphobilinogen desaminase 
PDT      photodynamic therapy 
PpIX     protoporphyrin IX 
ppm     parts per million 
psi     pound-force per square inch 
r. a.      relative abundance 
ROS     reactive oxygen species 
THF     tetrahydrofuran 
TLC     thin layer chromatography 
Zn     zinc 
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